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Abstract
Proteins perform various biological functions, e.g., as enzymes or transporters. In addition
to naturally occurring proteins, the use of protein therapeutic drugs for treating cancer and
other diseases is a rapidly growing area. A thorough biophysical characterization of
proteins and protein therapeutics opens the door to a more comprehensive understanding
of their role in health and disease. This dissertation aims to expand the capabilities of an
existing technique (Hydrogen Deuterium Exchange Mass Spectrometry, HDX-MS), which
is widely used for probing protein structure and dynamics. Conventionally, HDX-MS
experiments are performed as a function of labelling time. Here we aim to establish
temperature as a complementary variable. Our goal was to unravel the interplay between
thermally induced protein dynamic motions, unfolding, and aggregation.
Chapter 2 examined the effects of protein heating, using myoglobin (Mb) as model system.
MS was used to track deuterium uptake in response to increasing temperature at various
labelling time points. The resulting data were captured using a comprehensive temperatureand time-dependent HDX data analysis framework. The HDX trends were dissected into
contributions from “chemical” labelling, as well as local and global protein dynamics.
Experimental profiles started with shallow slopes and showed a sharp increase close to the
melting temperature. Our analysis revealed that local dynamics dominate at low
temperatures, while global events become prevalent closer to the melting point.
Chapter 3 studied the mechanism of thermally induced Mb aggregation. Upon heating, Mb
produced amorphous aggregates. The extent of aggregation was measured by
centrifugation and UV-Vis spectroscopy as a function of protein concentration,
temperature, and time. From these data, we conclude that aggregation likely proceeds from
globally unfolded proteins rather than from semi-unfolded species. The data obtained this
way paved the way toward extensive molecular dynamics simulations of protein
aggregation.
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In Chapter 4, we tested the applicability of the thermodynamic framework developed in
Chapter 2 to a monoclonal antibody (NISTmAb), representing a model system of a typical
protein therapeutic. Differential scanning calorimetry revealed the presence of three
successive melting points, reflecting the different stability of the CH2, CH3, and Fab
regions. HDX-MS was performed to comprehensively characterize the conformational
dynamics of NISTmAb as a function of time and temperature. Global analysis of the entire
data set yielded insights into the enthalpic and entropic behavior of different segments. The
unfolding of the Fab domain (which has the highest melting temperature) was found to be
closely coupled to aggregation. In summary, we developed a method that provides in-depth
information on the thermodynamic behavior of thermally stressed proteins based on HDXMS experiments, and we demonstrated the applicability of this method to proteins of vastly
different sizes and complexity.

Keywords
protein dynamics | hydrogen-deuterium exchange | mass spectrometry | myoglobin | protein
aggregation | protein thermal stability | monoclonal antibody | differential scanning
calorimetry | circular dichroism | thermodynamics
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Summary for Lay Audience
Proteins are essential biological molecules in every living organism. Proteins also play an
important role as therapeutics. For example, insulin has been used for decades in diabetic
patients, and antibody drug conjugates are increasingly being used for treating various
types of cancer. Unfavorable solvent conditions (such as heat and extremes of pH) can
cause protein unfolding and aggregation. Protein aggregation is also a common
characteristic of many neurodegenerative disorders such as Alzheimer’s and Parkinson’s
diseases. Pharmaceutical tests of new protein drugs routinely use thermal unfolding and
aggregation assays to assess the stability and shelf life of therapeutic proteins. However,
there remains an urgent need to develop new and improved methods for monitoring protein
thermal stability. With this in mind, the aim of the current thesis was to develop a better
understanding of thermally stressed proteins.
In Chapter 2, myoglobin, a small globular protein was used as model system. Myoglobin
was incubated in heavy water, and mass spectrometry was used to track deuterium uptake
in response to increasing temperature. We developed a novel model to interpret the
temperature- and time-dependent deuterium uptake data. Our analysis revealed that local
structural fluctuations dominate the protein behavior at low temperatures, while global
unfolding/refolding became prevalent close to the melting point.
Chapter 3 studied the mechanism of thermally induced myoglobin aggregation. The extent
of aggregation was measured by centrifugation and UV-Vis spectroscopy as a function of
protein concentration, temperature, and time. From these data, we concluded aggregation
proceeds from totally unfolded proteins rather than from semi-folded intermediates.
In Chapter 4, we tested the applicability of the thermodynamic framework developed in
Chapter 2 to a monoclonal antibody, representing a model system of a therapeutic protein.
Differential scanning calorimetry revealed that this multi-domain protein has three melting
points. Incubation of the antibody in heavy water at different temperatures and time points,
followed by mass spectrometry analysis, was conducted to comprehensively characterize
the conformational dynamics of the protein. Our data yielded insights into the
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thermodynamic behavior of different protein segments. In summary, we developed a novel
method that provides in-depth information on the thermodynamic behavior of thermally
stressed proteins.
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Chapter 1: Introduction
1.1 Proteins
Proteins are biological macromolecules that are involved in all physiological processes.
Genetic information is encoded in DNA, but it is put into action in the form of proteins.
Proteins are involved in the catalysis of biochemical reactions; they act as receptors for
cellular signals, facilitate the transport of small molecules, provide cellular structure, and
they protect the body against pathogens. Proteins have long been used medicinally, for
example, insulin1 (for treating diabetes), gamma-globulin2 (for boosting short-term
immunity), and protein-containing vaccines3 (for providing long-term immunity against
infectious agents). In recent years, numerous protein therapeutics have emerged that are
now being used to treat a number of diseases, including cancers and genetic disorders, in a
highly specific fashion.4, 5

1.1.1

Protein Structure

A protein typically consists of hundreds (sometimes thousands) of amino acids. Twenty
different types of canonical amino acids can be distinguished by their unique side chains
(“R” groups), which can be hydrophilic or hydrophobic. The amino acids with hydrophobic
side chains include alanine (Ala/A), valine (Val/V), proline, leucine (Leu/L), isoleucine
(Ile/I), methionine (Met/M), tryptophan (Trp) and phenylalanine (Phe/F).
On the other hand, the side chains of polar amino acids favor residing in an aqueous
environment. The amino acids with side chain that are polar but uncharged include serine
(Ser/S), threonine (Thr/T), tyrosine (Tyr/Y), asparagine (Asn/N), and glutamine (Gln/Q).
Residues that carry a net charge at pH 7 are most hydrophilic. Two of them are negatively
charged; glutamic acid (Glu/E) and aspartic acid (Asp/D), while two others are positively
charged; lysine (Lys/K) and arginine (Arg/R). Depending on pH, histidine (His/H) can
carry a charge or not, and for pH below 6 it is positively charged.
Peptide bonds allow amino acids to create polypeptide chains. A peptide bond is generated
by a condensation reaction between the carboxyl group of one amino acid and the amino
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group of the next residue (Figure 1.1). In the cell, these reactions are catalyzed by
ribosomes. The sequence of amino acids is called primary structure. This sequence also
determines the final three-dimensional structure of each folded protein. Intramolecular
hydrogen bonds between backbone amide and carbonyl groups give rise to secondary
structure elements such as α-helices or β-sheets.

Figure 1.1 Peptide bond formation between two amino acids.
Biologically active proteins have highly ordered tertiary structures that mediate specific
functions. These biologically active “native” conformations are created by consolidating
secondary structure elements. The hydrophobic effect is one of the driving forces for the
formation of tertiary structures. In addition, there are contributions from other interactions
such as salt bridges, van der Waals contacts, hydrogen bonds, and disulfide bonds. Some
proteins assemble further into quaternary structures consisting of several subunits. Each
subunit has its distinct primary, secondary and tertiary structure. (Figure 1.2)
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Figure 1.2. Protein structure (PDB ID 1AXC). (A) primary structure. (B) Secondary
structure. (C) tertiary structure (D) quaternary structure.

1.1.2

Protein Folding and Dynamics

In principle, each protein can adopt many different structures. According to the Boltzmann
distribution, the equilibrium population of any possible conformer is given by its free
energy. Under physiological solvent conditions, the native state (N) has the lowest free
energy, so the formation of this conformation from the unfolded state (U) is a spontaneous
process. This fundamental principle was uncovered by Christian Anfinsen, who received
the 1972 Chemistry Nobel Prize.6 On its folding trajectory from U to N, the protein may
pass through several intermediates. Intermediates along the folding pathway have a
successively lower free energy, thereby guiding the protein toward N on the free energy
landscape.7 (Figure 1.3)
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Figure 1.3 Proteins fold from the unfolded state to the native state via several
intermediates. Each conformation is characterized by its free energy relative to N.
Although it is undeniable that proteins require a properly folded structure to carry out their
biological tasks, native proteins in solution are not static but fluctuate between different
conformational states.8 The interconversion rates between these conformers are governed
by the barrier heights separating them, and their populations are determined by Boltzmann
weights, as noted above. Protein function is closely correlated with these dynamic motions.
Proteins are the molecular machines of biological systems, and proper dynamics have been
an integral aspect of their evolutionary selection.9 These conformational dynamics range
from fast vibrations of interatomic bonds to complete folding/unfolding fluctuations. These
events can occur on time scales ranging from ps to minutes.10 It has taken the effort of
theorists and experimentalists from the fields of physics, chemistry, and biology to
gradually uncover the connections between structure, dynamics, and function.11
As an example of the essential role of conformational dynamics, myoglobin, a small protein
that stores oxygen in muscle cells, was the first protein to have its three-dimensional
structure deciphered.12 However, it was instantly realized that dynamic motions are
required for its biological function since the crystallized protein lacks an open pathway for
oxygen to enter and exit the binding site on the heme.13 Fluctuations of the distal histidine,
which blocks the path in the crystal structure, appeared to mediate a quick route for oxygen
to reach its binding site.14 Myoglobin was used as a model system for several
multidisciplinary studies in protein science, and it was even referred to as the "hydrogen
atom of biology”.15 The experiments in Chapters 2 and 3 will focus on myoglobin as well.
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1.1.3

Antibodies

Antibodies are glycoproteins that belong to the Immunoglobulin (Ig) family and are part
of the immune system. They can recognize and destroy pathogens such as viruses and
bacteria. Contact of these pathogens with B-cells causes the production of antibodies. The
pathogens that trigger an immune response are called antigen. Antibodies can detect and
bind with specific surface features of the antigen, leading to antigen neutralization and/or
phagocytosis16 (Figure 1.4).

Figure 1.4 Antibody functions. (A) Neutralization; antibodies can bind and inactive the
antigen by neutralizing viral infectivity. (B) Opsonization; antibody bind to the antigen and
a phagocytic cell seizes the antibody-antigen complex and ingests it.
Antibodies are Y-shaped structures that consist of two identical heavy chains and two
identical light chains that are linked by disulfide bonds. Each heavy chain has one variable
domain (VH) and three constant domains (CH1, CH2, CH3). Both light chains have one
variable (VL) and one constant domain (CL). Each of the two Fab arms comprises CH1
and CL, along with VH and VL, which form the Fab moiety that is responsible for antigen
binding. The Fc substructure consists of CH2/CH2’ and CH3/CH3’ domains, the former
being decorated with N-linked glycans.17 (Figure 1.5)
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Figure 1.5 Cartoon representation of an IgG1 mAb. Disulfides are represented as dashed
orange lines, “G” indicates glycans.

The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. Specific antibodies
generated by the immune system can neutralize the virus and prevent it from being
infectious. Such “neutralizing” antibodies block the receptor binding domain (RBD) on the
SARS-CoV-2 spike protein, preventing it from binding with the ACE2 receptor on the
surface of the lung and other tissues.18 Figure 1.6 illustrates how the RBD interacts with
the Fab domain of an antibody.
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Figure 1.6 Structure of COVID-19 virus spike receptor-binding domain complexed with a
B38 neutralizing antibody (pdb code 7BZ5).

Monoclonal antibodies (mAbs) are laboratory-produced molecules with the same
homogeneous sequence and structure that bind to only one unique epitope on the antigen.
In contrast, polyclonal antibodies represent a mix of various proteins that bind to multiple
epitopes (Figure 1.7).
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Figure 1.7 Antibody (green) binding to antigens (orange). (A) polyclonal antibody can
bind to multiple epitopes. (B) monoclonal antibodies bind to the same epitope.

Therapeutic mAbs were introduced as drug candidates in the 1980s by Jerne, Köhler and
Milstein, who jointly awarded the 1984 Nobel Prize in Physiology or Medicine. mAbs are
becoming increasingly popular as novel types of medicines.19 Antibody-drug conjugates
(ADCs) are mAbs that have been coupled to cytotoxic chemicals.20 They originated as a
targeted therapy for treating diseases and are extensively used for cancer treatment. ADCs
can be utilized for drug delivery by binding receptors on the surface of cancerous cells.
Paul Ehrlich, a physicist who won the 1913 Nobel Prize, was the first to propose this
strategy, which he called the ‘magic bullet’ that relies on the directed transport of
chemotoxic chemicals to treat microbial infections or tumors. However, it took over 40
years to achieve successful clinical trials on ADCs.21 One therapeutic option for the
treatment of cancer is traditional chemotherapy. However, this approach is frequently
linked to poor therapeutic response and significant toxicity against normal healthy tissues
due to its low selectivity towards tumor cells. ADCs, as opposed to traditional
chemotherapy, target and destroy tumor cells while minimizing the damage to healthy
tissues.22
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ADCs have three components, (1) the mAb that selectively binds to the antigens on the
surface of tumor cells, (2) a cytotoxic substance that can kill target cells once it has been
absorbed and released from the mAb, (3) the linker that binds the cytotoxic agent to the
mAb. This linker has to have high stability in the circulatory system, but in the tumor cell
it must be able to release the cytotoxic molecule. The mechanism of ADCs for treating
cancer is as follows (Figure 1.8): 1) the mAb selectively attaches to the tumor cell; 2) it is
internalized in the cell by endocytosis ; 3) lysosomes degrade it; and 4) the cytotoxic
molecule is released leading to cell death (apoptosis).23, 24

Figure 1.8. Antibody drug conjugate (ADC) mechanism as a targeted therapy for cancer.

In 2000, the first ADC was approved by the United States Food and Drug Administration
(FDA) to treat acute myeloid leukemia, which is a cancer of the blood and bone marrow.25,
26

From 2011 to 2018, FDA approved four other ADCs, whereas from 2019 to 2020 five

more ADCs approved by FDA and entered the market for treating cancer.27 Currently, over
100 ADCs are being investigated in the clinical stages.23
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1.2

Native vs. Unfolded Proteins

Under physiological solvent conditions (ambient temperature, no denaturants, near-neutral
pH), the native state “N” is the preferred conformation. Hydrophobic amino acids are
predominantly buried in the protein core, while polar residues are mostly found on the
surface.28 According to the iceberg model, the poor solubility of nonpolar solutes in water
is mainly due to entropic reasons. Bulk water is highly dynamic, corresponding to a high
entropy. The formation of a partially ordered layer of “iceberg water” around hydrophobic
surfaces induce entropically unfavorable ordering, thereby promoting the formation of a
hydrophobic core. In contrast, hydrophilic/charged residues on the exterior of natively
folded proteins interact favorably with water, mainly via hydrogen bonds.29
By exposing a protein to denaturing agents (discussed in more detail below), the native
state can be disrupted, resulting in protein unfolding. Denaturants play a crucial role for in
vitro experiments for probing protein stability. The unfolded state “U” is biologically
inactive and has traditionally been described as a random coil. However, it is now well
established that U can retain considerable residual structure.30 For cooperative unfolding
transitions, there is an apparent two-state equilibrium involving N and U, without any
intermediates (Figure 1.9).31

Figure 1.9. Reversible two-state unfolding equilibrium. The native state is highly ordered,
whereas the unfolded state has a largely disordered structure.

The equilibrium constant of a two-state unfolding reaction is
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=

[ ]
[ ]
Equation 1.1

Where [U] and [N] are the equilibrium concentrations of the unfolded and native states,
respectively. The free energy difference ∆G° = GU°-GN° determines how strongly U and N
are populated. The relationship between the free energy of unfolding and the equilibrium
constant can be expressed as follows

=

−∆ °

Equation 1.2
Where R is the gas constant and T is the absolute temperature. ∆G depends on enthalpy and
entropy according to

∆ °=∆ °− ∆ °
Equation 1.3
N is stable if the N ⇄ U equilibrium has a positive ΔG; conversely, unfolding proceeds
spontaneously when ΔG < 0. Various factors contribute to the enthalpic (ΔH) and entropic
(ΔS) terms in equation 1.3. For ΔH, by exposing a protein to denaturants, H-bonds, van der
Waals and hydrophobic interactions are destabilized. On the other hand, the unfolded
protein forms new H-bonds with the surrounding water that stabilize U. With respect to
ΔS, the unfolded state has more conformational freedom and, therefore a higher
conformational entropy. On the other hand, surrounding formerly buried hydrophobic
groups with iceberg water after unfolding is entropically unfavorable (Figure 1.10).32
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Figure 1.10. The thermodynamics of protein unfolding depend on various factors. For
the scenario described here, the native state will spontaneously unfold.

1.2.1

Chemical Denaturants

By exposing natively folded proteins to chemical denaturants such as guanidinium chloride
(GdmCl) and urea, the stability of the native state N is reduced, and the protein will
transition to the unfolded state U (Figure 1.11). Concentrations required for unfolding are
typically ~6 M for GdmCl, and ~ 8 M for urea.

Figure 1.11. Guanidinium Chloride and urea are common chemical denaturant.
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Both polar and nonpolar side chains have a higher solubility in denaturant solutions than
in pure water. It has been suggested that these denaturants interact favorably with all parts
of the protein and reduce the hydrophobic effect. The extent of these interactions is
maximized when the protein is unfolded. Computer simulations suggest that both
denaturants reduce the hydrophobic effect by modifying the internal structure of water.33
From equation 1.2, the stability of a protein can be expressed as
∆ °

→

=−

[ ]
[ ]

=−

Equation 1.4
∆G°N → U is found to change linearly with denaturant concentration [D] according to
∆ °= ∆ °

−

[ ]
Equation 1.5

The slope of this equation (m) relates to the change in the protein's solvent-accessible
surface area upon unfolding.34 Typical m values for urea and GdHCl are 4 and 12
kJ/mol/M, respectively. Figure 1.12 A shows a typical curve of ∆G° versus [D]. In Figure
1.12 B, the fraction of unfolded protein fU = [U]/([N]+[U]) is plotted as a function of
denaturant concentration, using the Boltzmann expression fU = exp(-∆G/RT) / [1 + exp(∆G/RT)]. [D]50 is the denaturant concentration for which half of the proteins are unfolded,
and the other half is still native. Under these condition ∆G°=0 and [U]= [N]. Therefore:
∆ °

=

[ ]
Equation 1.6
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Figure 1.12. (A) Free energy (∆G°) profile of chemical unfolding as a function of
denaturant concentration [D], based on equation 1.5. While the parameters were:
∆G°water= 30 kJmol-1; m=5 kJ mol-1 M-1; T= 298 K. (B) Fraction of unfolded protein
f=[U]/([U]+[N]) as a function of [D], calculated from ∆G° values shown in (a). When
[D]50= 6 M, ∆G° becomes zero and [N]=[U].
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1.2.2

Thermal Unfolding

Thermal unfolding assays are widely used for assessing protein stability, particularly for
mAbs and other therapeutic proteins.35 In these experiments, a protein is exposed to
gradually increasing temperatures, and fU (T) is measured until the protein is completely
unfolded. 36
Equation 1.3 shows that ΔG is dependent on temperature. From the simple facts that H >
0 (unfolding is endothermic) and S > 0 (unfolding increases entropy), it follows that an
increase in T will result in G < 0 once the temperature is raised beyond a specific value
which is referred to as melting temperature Tm.. In other words, for T > Tm the protein will
be unfolded. The situation can be more complicated because H and S change as a
function of temperature (Equations 1.7 and 1.8).37

∆ °=∆ ° + ∆

( −

)
Equation 1.7

∆ °=∆ ° + ∆
Equation 1.8
The temperature dependence expressed in equations 1.7 and 1.8 implies that ∆G°(T)
profiles are curved instead of being a straight line (Figure 1.13). When we assume Cp =
0, G depends linearly on temperature, while for Cp > 0, the curvature of G is readily
apparent (Figure 1.13A). As for chemical unfolding, fU can be calculated from the G(T)
profiles.
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Figure 1.13. (A) plot of the free energy of thermal unfolding (∆G°) as a function of
temperature. (B) Fraction of unfolded protein, calculated from the free energy profile.
Parameters used: ∆Cp=1.5 kJmol-1 K-1, ∆H°R= 180 kJ mol-1 and ∆S°R= 0.52 kJ mol-1 K-1.
Here, the melting temperature of Tm= 350 K is identical to the reference temperature TR.

1.2.3

Protein Aggregation

Protein-protein interaction plays an essential role in biology, for example, when several
protein chains assemble into highly ordered quaternary structures. However, some types of
protein-protein contact are detrimental to human health.38 The interior of biological cells
is highly crowded, giving rise to possible nonspecific interactions between proteins and
other molecules that can lead to aggregate formation. Protein aggregation depends on
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solution conditions, such as temperature, pH, salt and buffer condition, agitation, surfactant
effects, and protein concentration.39 Aggregated proteins are often insoluble, resulting in
precipitates that give rise to “cloudy” or milky” solutions. After synthesizing a polypeptide
chain on a ribosome, the chain may fold to its native structure via one or more partially
folded intermediates. In the cell, the situation is even more complex due to the involvement
of chaperones, i.e., proteins that ensure efficient folding and prevent aggregation.40
Unfolded or partially folded proteins can undergo aggregation:
Native  Aggregated
Native ⇄ Partially Folded  Aggregated
Native ⇄ Unfolded  Aggregated
Aggregates can be disordered and amorphous, or they can be highly ordered and fibrillar.
The latter are called amyloid fibrils; they are rich in β-sheet structure and can form from
almost any amino acid sequence.40 These β-sheet structures are not related to native
conformations; for instance, although native myoglobin has an all α-helical globular
structure, it can transition into a fundamentally different conformation that shows typical
characteristics of amyloid fibrils.41
Misfolding and aggregation are associated with a host of human diseases,42 known as
amyloidosis. Many of these are neurodegenerative disorders such as Alzheimer’s, where
aggregates form in the brain, or type II diabetes, where deposits form in the pancreas.43
Some amyloidogenic proteins called “prions” can transmit their misfolded shape onto
normal protein via a templating mechanism, and they are responsible for Creutzfeld-Jakob
disease in humans or “mad cow disease” (BSE) in cattle.44
Aggregation is also a major concern during the production and storage of
biopharmaceuticals. For commercializing protein therapeutics, physical and chemical
instability are key challenges.45 Protein aggregation is the most common source of
instability throughout the product development pipeline.46
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Aggregation is caused by non-native intermolecular interactions. The native state only has
the lowest free energy when considering an isolated protein in solution (or a protein at a
low concentration). The native state is typically only about 20-80 kJ mol-1 lower in free
energy than the unfolded state. This thermodynamic stability is marginal, considering that
single covalent bonds have energies of ∼300 kJ mol-1.47 Aggregates represent the lowest
free energy state in concentrated protein solutions, making aggregation thermodynamically
favorable under such conditions. The mechanisms underlying protein aggregation remain
poorly understood, and the relationship between unfolding and aggregation is a subject of
great interest. The route from the native state to various aggregates may proceed through
different monomeric precursor species. The exact nature of these precursor species remains
to be established.48

1.3
1.3.1

Methods for Studying Protein Thermal Stability
Circular Dichroism (CD) Spectroscopy

Circular dichroism spectroscopy is an absorption-based technique widely used for
monitoring protein secondary structure and tertiary structure.49 There are two ways that
light can be circularly polarized: left and right. In CD spectroscopy, a monochromator is
used select linearly polarized light of a specific wavelength. Circularly polarized light is
generated by passing this beam through a modulating device, often a photo-elastic
modulator (PEM). Chiral molecules absorb left (εL) and right (εR) circular polarized light
differently. A CD spectrum measures the difference in light before and after passing
through the protein solution (Figure 1.14). A CD spectrum is a plot of (εL – εR) versus
wavelength (λ).50 This wavelength dependence is uncovered by slowly scanning the
monochromator.
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Figure 1.14. Schematic layout of a CD experiment.

Far-UV CD signals (180-250 nm) of the polypeptide backbone report on protein secondary
structure. A negative peak at 195 nm indicates the prevalence of random coil structure,
while two negative peaks (222 and 208 nm) and one positive peak (192 nm) indicate a high
percentage of α-helical segments. In addition, one negative peak (218 nm) and one positive
peak (195 nm) serve as indicators for β sheets (Figure 1.15).50
One of CD spectroscopy's most typical applications is monitoring conformational changes,
i.e., unfolding fU (T). 222 nm represents the most common detection wavelength. Many CD
instruments have cuvettes that allow the temperature of the sample to be controlled for
monitoring thermal unfolding. Although widely used, CD spectroscopy cannot provide
structural information at the residue level.51
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Figure 1.15. Cartoon diagram of CD spectra that represent principal polypeptide
secondary structures (α-helix, β-sheet and random coil).

1.3.2

Differential Scanning Calorimetry (DSC)

The heat capacity Cp(T) of a protein can be determined using differential scanning
calorimetry (DSC). Throughout the experiment, the sample and reference are kept at the
same temperature. The sample and reference holder temperature rise linearly as a function
of time, and heat flow into or out of a sample is monitored (Figure 1.16).52
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Figure 1.16. Schematic layout of a DSC instrument.

The ratio of heat flow to heating rate reflects the heat capacity according to

Cp =

∆
∆

=
Equation 1.9

The enthalpy of unfolding (ΔH) is obtained by integrating the area under the Cp(T) peak,
and the baseline offset between U and N represents the ΔCp term that was introduced in
equations. 1.7 and 1.8.
∆Cp= CP(U) -CP (N) > 0

Equation 1.10
Similar to CD-based unfolding experiments, DSC only reports on global unfolding
transitions. However, for multi-domain proteins such as mAbs, DSC often shows several
maxima that reflect the sequential unfolding of different regions at different melting
temperatures.
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Figure 1.17. Cartoon depiction of a DSC thermogram that shows the thermal denaturation
of a protein.

1.4
1.4.1

Mass Spectrometry
Fundamentals of Mass Spectrometry

Mass spectrometry (MS) is a widely used analytical tool for numerous (bio)analytical
applications. In recent years this technique has become particularly important for proteinrelated studies, i.e., proteomics and “biophysical” MS. The origins of MS go back to the
early 20th century.53 MS can be coupled with analytical separation techniques such as liquid
chromatography (LC)54, gas chromatography (GC)55 and capillary electrophoresis (CE)56.
MS measures the mass to charge ratio (m/z) of ions in the gas phase. Therefore, an ion
source and a mass analyzer are essential components of any MS instrument. Additional
information can be provided by incorporating other features such as ion mobility devices,
collision cells, etc.
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1.4.2

Ion Source

As the first step of any MS experiments, the analyte(s) of interest must be ionized and
subsequently transported into the vacuum of the mass analyzer. A variety of ionization
techniques have been developed over the years. Every type has its unique advantages and
drawbacks. The most effective and extensively used ionization method for biological
samples is electrospray ionization (ESI).57 This technique generates intact gaseous ions
directly from analytes in the solution. Consequently, ESI can be easily coupled with high
performance

liquid

chromatography

(HPLC)

and

ultra-performance

liquid

chromatographic (UPLC). This capability significantly broadens the scope of MS for
various analytical applications.58 Additionally, ESI is a "soft" ionization method, that does
not rupture covalent bonds. Native MS refers to a unique “flavor” of ESI, where the aim is
to preserve noncovalent connections within the protein as well as contacts to weakly bound
binding partners.59 Figure 1.18 displays an example of a native ESI mass spectrum.

Figure 1.18. A native mass spectrum of ubiquitin at pH 7

Multiply charged [M + zH] z+ ions are produced via ESI. The mass to charge ratio m/z of
a specific ion can be calculated as
=

+ × 1.008

Equation 1.11
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where M is the mass of the neutral analyte, 1.008 is the proton mass, and z is the charge
state. This equation assumes that protonation is solely responsible for the analyte charge.
Under experimental conditions, some cationization (involving Na+ or K+) may take place
as well.
Although ESI is the most common method for biological samples, it is not the only
ionization method. Numerous other ionization sources can be used, such as electron
ionization (EI), chemical ionization (CI), atmospheric pressure chemical ionization
(APCI), matrix-assisted laser desorption ionization (MALDI), desorption electrospray
ionization (DESI), paper spray ionization (PS), and several others.60

1.4.3

Mass Analyzer

The mass analyzer's purpose is to measure the m/z as well as the relative abundance of
gaseous ions produced by the ion source. Mass analyzers come in a variety of technologies,
including quadrupole, time-of-flight (TOF), ion trap, Orbitrap, and Fourier transform ion
cyclotron resonance (FT-ICR) instruments.61 Quadrupoles and time-of-flight (TOF) mass
spectrometers will be explained briefly here.

1.4.3.1

Quadrupole Mass Analyzer

In a quadrupole mass analyzer, four cylindrical rods are arranged in parallel. Opposing rod
pairs receive a direct current (DC) and a radio frequency (RF) voltage. For any combination
of RF and DC voltages, only ions with one specific m/z have stable trajectories, allowing
them to pass through the quadrupole and arrive at the detector. All other ions have unstable
trajectories, collide with the rods, and are neutralized. The Mathieu equations can be used
to predict the ion trajectories for every given combination of RF and DC voltages.62 By
scanning the RF and DC voltage amplitudes, one can change the m/z range that is being
transmitted, thereby generating a mass spectrum.
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Quadrupoles can also serve as ion guides that transmit any m/z when operating them in the
RF-only mode (without a DC voltage). Consequently, quadrupoles are frequently
employed in MS/MS applications as adjustable ion transmission and selection devices.63
Quadrupoles are exceptionally resilient tools that have remained a standard in
environmental and pharmaceutical labs despite their poor resolution and long scanning
durations.64

1.4.3.2

Time of Flight (TOF) Mass Analyzers

Ions are separated by a TOF mass analyzer based on how quickly they pass through a flight
tube. By applying a voltage, U, an ion pusher accelerates ions in a flight tube.65 The ion
velocity v can be calculated by using the equation
=

1
2
Equation 1.12

The equation for the time of flight (t) that an ion needs to travel through the flight tube with
length l is given by:
= =

/

= (2 )

/

/

Equation 1.13
This equation shows that the time of flight depends on the m/z of the ion. Thus, ions with
different m/z values have different flight times, which causes them to be separated in the
flight tube. Lower m/z ions reach the detector first, followed by their heavier counterparts.
Modern TOF mass spectrometers also employ a reflectron to enhance the spectral
resolution. Ultimately, a time-to-digital converter that assigns flight times to specific
m/z.values,66
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One of the most widely used instrument designs for biomolecular analysis, known as QTOF, results from combining quadrupole and TOF technology.67 (Figure 1.19).

Figure 1.19. Schematic layout of the Q-TOF instrument. The yellow line indicates the ion
path.

1.4.4

High
Performance
Liquid
Spectrometry (HPLC-MS)

Chromatography

Mass

High performance Liquid Chromatography (HPLC) is a technique for separating a sample
into its components. In this technique, the mobile phase is a pressurized liquid that mediates
convective analyte transport through a column that is packed with solid adsorbent material
(stationary phase). This stationaryphase has different affinity for different components in
the sample, causing different retention behavior for different components, and thereby
separating the mixtures as they elute from the column. In HPLC-MS, physical separation
of liquid chromatography is combined with the capability of measuring the m/z of analytes
to enhance chemical analysis. In summary, HPLC separates different mixtures of
components (proteins, peptides, etc.), while MS provides information for detecting each
separated component.68 UPLC is a term used by one specific manufacturer (Waters INC);
it refers to the same principle as HPLC, albeit with improved performance due to smaller
particle size and higher pressures.
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1.5
Hydrogen Deuterium Exchange Mass
Spectrometry (HDX-MS)
Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) has become a widely used
method for studying protein structure and dynamics. This technique relies on the fact that
backbone amide hydrogens can be exchanged with deuterium upon protein exposure to a
D2O solvent environment. The deuteration rates are highly sensitive to protein structure
and dynamics. In the native state, most backbone NH sites are involved in intramolecular
H-bonding with backbone CO groups. These H-bonded sites are protected and undergo
relatively slow HDX.69 In contrast, disordered and unfolded regions lack stable H-bonds,
resulting in much more rapid HDX.70
During typical “continuous labeling” HDX-MS experiments, a protein in H2O is diluted
into D2O solution under the desired conditions (usually buffer at pD 7). Aliquots are
removed at specified time points, and HDX is quenched by rapidly decreasing the pH to
2.5 and immersing the sample in liquid nitrogen. The deuterium uptake into the protein is
then measured as a function of labeling time by MS (Figure 1.20).

Figure 1.20 Workflow of a typical HDX-MS experiment.
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Alternatively, the experiments can be performed in a “pulsed HDX” fashion, where
deuteration only takes place for a relatively brief period of time, while some other variables
are altered. This second approach is helpful for studying transient folding intermediates.71
HDX experiments can be performed on intact proteins or in a spatially resolved fashion at
the peptide level. In the latter case, the sample is proteolytically digested after quenching
by an acidic protease such as pepsin. For modern workflows, pepsin is immobilized on a
digestion column designed for HPLC or UPLC. After digestion, the sample is loaded onto
a trapping column for desalting. Subsequently, the peptides are separated on an analytical
C18 column. An unavoidable drawback of this workflow is the occurrence of some back
exchange during which deuterated peptides lose a certain percentage of their deuterium as
they pass through the HPLC. Complete back exchange occurs in amino acid side chains,
while a relatively large fraction (often around 70% or more) of amide backbone deuterium
can be retained. To minimize amide backbone back exchange, the digestion column is
cooled to 15 °C, while the remaining flow path is kept just above 0 °C. The HPLC gradient
and flow rates are also optimized to minimize the retention time. Finally, the peptides are
analyzed online by ESI-MS, such that deuterium-induced mass shifts can be measured for
each peptide. Each amide backbone HDX event increases the protein (or peptide) mass by
1 Da. HDX-MS can be applied for identifying, mapping, and pinpointing the appearance
of dynamically fluctuating flexible regions.72

1.5.1

HDX Fundamentals

NH, OH, and SH groups in proteins can undergo deuteration upon exposure to D2O.
Because side chain sites undergo complete back exchange during HPLC, we only focus on
backbone NH sites. Most backbone NH sites in native proteins are involved in H-bonds (in
α-helices and β-sheets). This H-bonding implies that the corresponding sites exchange very
slowly. Their deuteration is mediated by conformational fluctuations (opening/closing
transitions) of the protein.32 These fluctuations may correspond to local, sub-global, or
global events.
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First, let us consider a scenario where HDX happens at completely open (random coil)
backbone amide sites that are fully solvent accessible and not involved in any H-bonding.
Deuteration under these conditions is referred to as “chemical exchange”, and it takes place
with the pseudo first-order rate constant kch. Chemical exchange can be catalyzed by either
acid or base according to
=

[

]+

[

]
Equation 1.14

where kH and kOH are the second-order rate constants for acid and base catalysis. These
values depend on the adjacent amino acid side chains. Hence, the primary structure impacts
HDX rates. For a polyalanine (which is considered to be a typical model), kch has its
minimum at pH 2.5 Thus, at pH > 2.5 the reaction is catalyzed by base. In other words, for
experiments performed under physiological conditions (pH 7) kOH plays the dominant role,
while kH effects are negligible.
kH and kOH depend on temperature T as governed by the Arrhenius equation
=
Equation 1.15
where Ea represents the activation energy and R is the gas constant.
The dependence of kch on pH and temperature for different protein sequences of was
uncovered by Englander et al.73-75 In Figure 1.21, kch for the third residue in polyalanine is
calculated based on their work. These figures illustrate why HDX can be quenched under
UPLC conditions by using pH 2.5 and ~0 C.
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Figure 1.21. Dependence of the chemical rate constant kch on (A) Temperature (B) pH
for the third residue in a polyalanine chain.

For backbone NH sites that are involved in H-bonds, HDX proceeds much more slowly
compared to the kch expressions discussed above. For HDX to occur, there have to be
transient H-bond opening events during which H-donor and acceptor are separated. Such
opening/closing events are mediated by thermal fluctuations of the protein, i.e., by its
conformational dynamics (equation 1.16).

−

−

−

Equation 1.16
In this equation, kop and kcl are opening and closing rate constants that describe the protein
conformational fluctuations. Equation 1.16 gives rise to two limiting cases. For kcl >> kch
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the situation is referred to as EX2, where numerous opening/closing events are required
before deuteration takes place. The overall HDX rate constant (kHDX) under these
conditions is given by
=
Equation 1.17
In contrast to EX2, when kch >> kcl, amides will exchange during the first opening event,
such that kHDX = kop. This so-called EX1 mechanism is characterized by bimodal isotopic
distribution in the mass spectra because nondeuterated and fully deuterated species coexist
in the sample.76
protection factor P is commonly used to report how much slower the measured kHDX value
is relative to kch (Equation 1.18).
=
Equation 1.18
Each amide hydrogen in a folded protein has a specific protection factor. Protection factors
for loops, termini and unfolded regions are lower (1-100) than those for tightly folded
regions (up to 106 and higher).

1.5.2

Peptide Mapping

Usually, the first step to processing bottom-up HDX data analysis is peptide mapping.
Data-dependent acquisition (DDA) is the traditional peptide mapping method in which the
most abundant precursor ions are selected for fragmentation, and MS/MS is applied to
identify the peptides via their b and y fragment ions. This process may have to be repeated
several times to identify all ions, and a survey scan and precursor selection is needed.
Besides, the collision energy may have to be optimized, which makes the processing time
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consuming. Also, during MS survey scans, only high-intensity ions will be picked up, and
important low-abundance species may be overlooked.77 Data independent acquisition
(DIA) is an alternative method for peptide mapping in which all ions are fragmented
without precursor selection. This second approach is also known as MSE. The collision cell
in the mass spectrometer is alternating between low and high collision energy, such that
precursor ions and their fragments can be recorded quasi-simultaneously as peptides elute
off the column. The retention time in LC-MS and signal intensity for each precursor are
correlated using computer software, such that precursor and fragment ions can be assigned
to one another.78

1.5.3

Data Analysis in HDX-MS

Back exchange is unavoidable in HDX-MS, especially during enzymatic digestion and
UPLC separation. To correct for back exchange, two types of reference samples have to be
prepared: a protein sample representing the maximum possible HDX uptake (m100), and a
sample under the quenched condition that was exposed to deuterated at with minimum time
(m0). The deuteration percentage for each time point %D (t) can be corrected by the
following equation:
−
−

% ( )=

× 100%
Equation 1.19

Where mt is the mass of peptide at a specific incubation time and temperature.
The deuteration behavior of a peptide with N non-proline residues covering amino acids k
to (k+N-1) can be described as

% ( )=

1
( − 2)

[ 1 − exp −
(

,

×

]

)

Equation 1.20
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where kHDX, is the HDX rate constant of NH i. Summation starts at k+2 because the first
two residues undergo complete back exchange during LC. From typical peptide-resolved
data it is not possible to extract kHDX,i for each individual amide. Instead, fits usually employ
one or two exponentials that yield average kHDX values.

1.6

Scope of Thesis

Understanding the properties of mAbs and other proteins requires a comprehensive
characterization of their structures and dynamics, their thermodynamic properties,
unfolding behavior and aggregation propensity. The aim of the current thesis is to expand
the analytical capabilities of HDX-MS to address all these topics.
Chapter 2 develops an HDX-MS framework that considers how elevated temperatures
affect protein structure and dynamics. In typical HDX-MS experiments, a native protein is
incubated in D2O at a constant temperature, and aliquots are removed at selected time
points. In addition to time-dependent HDX-MS, there is a rapidly growing interest in
conducting these measurements in a temperature-dependent fashion. Temperaturedependent data can yield a much more comprehensive view of protein dynamics. We were
able to quantitatively describe the temperature- and time-dependent HDX behaviour of the
model protein Mb.
Many challenges remain when it comes to understanding the mechanisms whereby proteins
undergo thermal aggregation. Chapter 3 focuses on the aggregation behavior of Mb. We
examined the response of Mb to heating to gain insights into the interplay of unfolding and
aggregation. Specifically, we attempted to determine what exactly constitutes the
aggregation-prone species in solution; possible candidates include the native state, partially
folded conformers, and the unfolded state.
In Chapter 4, our thermodynamic model from Chapter 2 was applied to the NIST reference
mAb, a complicated multi-domain system where dynamics, unfolding, and aggregation are
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closely intertwined. Our experiments aimed to demonstrate that complete HDX profiles
can be generated in as little as 30 s. With future automation of this workflow, it should be
possible to implement temperature-dependent HDX-MS workflows for high-throughput
applications in the pharmaceutical industry. Overall, it is hoped that the current work will
encourage practitioners to explore the use of temperature-dependent HDX-MS, instead of
being confined to traditional time-domain measurements.
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2

Chapter 2. Analysis of Temperature-Dependent H/D
Exchange Mass Spectrometry Experiments
2.1

Introduction

Native proteins undergo incessant thermal motions, from local fluctuations to global
unfolding/refolding.1, 2 These dynamics reflect the fact proteins continuously explore their
conformational space. The population of each conformer depends on its free energy,2 while
interconversion rates are governed by activation barriers.3 Protein dynamics are linked to
biological function such as catalysis,4 energy conversion,5 and signaling.6 However,
protein fluctuations can also generate structures that act as gateway to cytotoxic
aggregates.7, 8
Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) is one of the most widely
used tools for interrogating protein dynamics.5,

8-15

HDX-MS complements other

techniques such as Förster resonance energy transfer, time-resolved X-ray diffraction, and
NMR spin relaxation studies.16 HDX-MS monitors the deuteration of backbone NH groups
upon exposure to D2O. In native proteins most of these sites are engaged in NH···OC
hydrogen bonds. According to the widely accepted Linderstrøm-Lang model (equation
2.1)2, 17 native state HDX is mediated by opening/closing (unfolding/refolding) fluctuations
that transiently disrupt H-bonds.

NH closed

kop




kcl

NHopen

kch

D 2O

exchanged

Equation 2.1
Here, kop and kcl are the opening and closing rate constants, and kch is the “chemical” rate
constant.18 HDX usually proceeds in the EX2 limit (kcl >> kch),2 where each NH undergoes
many opening/closing transition before it is deuterated. The overall HDX rate constant in
this case is
kHDX = Kop  kch
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Equation 2.2
where Kop = kop/kcl. Hence, HDX kinetics are governed by NHopen sites, even though the
population of these sites tends to be very low (typically << 1%).2, 19, 20 Dynamic regions
(larger Kop) exhibit faster HDX, while labeling of rigid segments (smaller Kop) proceeds
more slowly.
In conventional HDX-MS a protein is incubated in D2O at constant temperature. Aliquots
sampled at various time points are subjected to proteolysis, followed by LC/MS to uncover
the deuteration percentage (%D) of individual peptides. In addition to these conventional
measurements, there is growing interest in temperature-dependent HDX-MS. The latter
can provide a more comprehensive view of protein dynamics.21-29 Of particular importance
is the characterization of thermally stressed protein drugs (such as therapeutic antibodies)
to assess their stability and aggregation propensity.15, 30, 31
It is well known that elevated temperatures tend to enhance HDX,21-29 but the origins of
this effect are non-trivial. Temperature controls HDX via two avenues. (1) The labeling
chemistry (kch in equation 2.1) accelerates quasi-exponentially with temperature18 due to a
combination of Arrhenius behavior and changes in the concentration of OD- catalyst.32, 33
(2) Temperature governs the Boltzmann populations of NHopen states,2 and it alters the
protein energy landscape.34 HDX-MS aims to uncover protein behavior (contribution 2),
but unfortunately this aspect tends to be masked by temperature-dependent changes of kch
(contribution 1). Preliminary steps have been taken to unravel this problem,20, 25, 35-37 but a
comprehensive strategy for analyzing HDX-MS data as a function of temperature (T) and
time (t) is still lacking. The current work fills this void by deconvoluting experimental
HDX-MS data into the two aforementioned contributions.
Protein stability studies usually rely on a two-state approximation involving the native state
N and the unfolded state U.34 The free energy of the global N  U equilibrium is
Gglob = Hglob – T Sglob
Equation 2.3
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N is stable as long as Gglob > 0. Simple analyses often assume that enthalpy (Hglob > 0)
and entropy (Sglob > 0) are constant, such that Gglob depends linearly on T.38 Heating
causes Gglob to turn negative at the melting temperature Tm, thereby triggering unfolding.
A more thorough treatment of equation 2.3 has to consider Cp, the heat capacity
difference between U and N which causes Hglob and Sglob to become T-dependent (Cp
> 0)34

Hglob(T) = Hglob(Tm) + Cp  (T - Tm)
Equation 2.4a
Sglob(T) = Sglob(Tm) + Cp  ln(T/ Tm)
Equation 2.4b
where Sglob(Tm) = Hglob(Tm)/Tm.38 Equation 2.4 implies that Gglob(T) is curved. As a
result, proteins are most stable at an intermediate temperature. Raising the temperature
beyond Tm triggers heat-induced unfolding. Cooling causes destabilization as well;
depending on the magnitude of Cp this can cause cold-unfolding.39-41
Equations 2.3 and 2.4 are key pillars of protein thermodynamics.34,

38

However, it is

undisputed that two-state N  U models do not fully capture the protein behavior,
especially

at

ambient

T

where

local

fluctuations

dominate

over

global

unfolding/refolding.1, 2 For addressing this deficiency and for interpreting T-dependent
HDX-MS data it is necessary to combine the Linderstrøm-Lang model (equations 2.1, 2.2)2,
17

with the thermodynamic principles expressed in equations 2.3 and 2.4.

Building on the aforementioned ideas, the current work devises a strategy for analyzing Tdependent HDX-MS data. Like many previous studies on protein thermodynamics,39
folding,42 fluctuations,1 and aggregation,43 we chose the heme protein myoglobin (Mb) as
model system. Mb has a globular native structure, where a hydrophobic core is surrounded
by solvent-exposed polar and charged residues.44 We tracked the HDX response of Mb to

42

changes in T, and we captured the resulting data using a comprehensive T- and t-dependent
HDX data analysis framework.

2.2
2.2.1

Methods
Materials

Horse-heart ferri-Mb (Sigma, St. Louis, MO) samples were centrifuged to remove small
amounts of insoluble debris. All solutions contained 50 mM sodium phosphate buffer and
100 mM NaCl at a pH meter reading adjusted to 7.2 (corresponding to pD 7.6 for D2Obased solutions).18, 45 This value was T-independent with deviations of less than  0.1,
consistent with previous reports on the temperature stability of phosphate buffer.46

2.2.2

Optical Experiments

Circular dichroism (CD) spectra were recorded on a Jasco J-810 spectropolarimeter
(Easton, MD) with a 1 mm cuvette using 5 µM Mb between 20 °C and 96 °C. Unfolding
profiles were generated by monitoring the CD signal at 222 nm which is characteristic of
-helical secondary structure.47 These CD222 profiles were analyzed by using38, 48

=

(

+

)+( +
)exp (−∆
1 + exp (−∆
/ )

/

)

Equation 2.5

where (yN + mNT) and (yU + mUT) are the sloped pre- and post-transition baselines,
respectively, with Gglob = Hglob(1 – T/Tm).
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2.2.3

H/D Exchange Mass Spectrometry

HDX was performed by adding 50 M Mb solution in H2O buffer to D2O labeling buffer
in a 1:9 ratio, for a final protein concentration of 5 M in 90% D2O. All measurements
were performed with careful temperature control, by placing the samples in Eppendorf
tubes that were immersed in a water bath during labeling. An ice/water mix was used for
measurements at 0 C, while HDX between 23 C and 80 C was performed by employing
a heated circulating bath. Prior to initiating HDX, D2O labeling buffer was pre-equilibrated
at the desired temperature, while Mb was kept at 23 C to avoid aggregation in the stock
solution. Two types of HDX experiments were performed. (i) [variable T, constant t] was
conducted by using a deuteration time of t = 30 s. (ii) For [constant T, variable t] aliquots
were removed at t = 30 s, 10 min, and 100 min. HDX was quenched by mixing with HCl,
resulting in a pH meter reading of 2.4. This was followed by flash freezing and storage in
N2(l). For analysis, the samples were rapidly thawed and injected into an Acquity HDXUPLC (Waters, Milford, MA). Digestion was performed on an immobilized pepsin column
(Thermo Fisher) at 15 C. Peptides were separated on a 1.7 µm BEH130 C18 2.1 mm ×
100 mm column using a 20 min water/acetonitrile gradient in the presence of 0.1% formic
acid at ~0 C. The sequence coverage was 98% (Figure 2.1).
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Figure 2.1. Peptic digestion map, showing the HDX sequence coverage (image generated
by Waters DynamX).
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Blanks were injected to prevent carryover. In addition, the pepsin column was washed with
1.5 M guanidine hydrochloride in water/acetonitrile/formic acid (95.2/4/0.8) after each
digestion step. The UPLC was coupled to a Waters Synapt G2 mass spectrometer with a
lock spray dual electrospray source. The identity of each peptide was confirmed by MSE
on non-deuterated samples with data analysis by Waters PLGS 2.5.3, based on the known
Mb sequence (pdb 1wla44). The capillary voltage and desolvation temperature were +2.8
kV and 250 °C respectively. The centroid mass of each peptide isotope distribution was
calculated using DynamX 3.0 (Waters) and converted to percent deuteration (%D)
according to %D = [(m – m0)/(m100 – m0)]  100%, where m is the centroid m/z for the
peptide of interest. m0 and m100 correspond to minimally and fully deuterated controls,
respectively. The former were prepared by adding Mb to pre-quenched D2O buffer,
followed by flash freezing. m100 samples were prepared similar to m0 samples, except that
they were incubated for 3 days at 37 C. Back-exchange levels determined from m100
samples were (38  14)%, similar to previous reports.35, 49 All %D values are averages of
three independent replicates; error bars represent standard deviations.
Elevated temperatures may cause protein aggregation50 which would complicate the
interpretation of HDX and CD experiments. Aggregation can be suppressed by working
with dilute solutions.42, 51 For the experiments of this work we therefore used a relatively
low Mb concentration (5 M), where aggregation was negligible for at least 20 min even
when heated to 358 K (85 C). This assertion is based on aggregation assays on Mb that
had been heated for different t and T, followed by centrifugation and UV-Vis analyses of
the supernatant.
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2.3
2.3.1

Results and Discussion
Spectroscopic Characterization of Global Unfolding

Heat-induced unfolding of Mb was probed by CD spectroscopy. Spectra acquired at
different T intersected at ~204 nm (Figure 2.2A). This isodichroic point is consistent with
a global N  U transition,39, 52 justifying the application of equations 2.3 and 2.4. Thermal
unfolding profiles were recorded by monitoring CD222 at different heating rates (1 C min1

and 4 C min-1) in both H2O and in D2O. All of the resulting CD222 profiles were very

similar, with Tm = 356.2  0.6 K and Hglob(Tm) = 453  20 kJ mol-1 (Figure 2.2B).
As is common practice in optical melting experiments,38 the aforementioned analysis
assumed that Cp = 0, such that Gglob depends linearly on temperature (Figure 2.2C,
dotted line, equation 2.3). Alternatively, one can perform an analysis with Cp = 8 kJ mol1

K-1, a value determined by differential scanning calorimetry (DSC).39, 53 This Cp value

with the Tm and Hglob(Tm) noted above corresponds to a curved Gglob profile (Figure 2.2C,
solid line, equation 2.4). Both Gglob profiles match the experimental data equally well
(Figure 2.2B), but the curved profile in Figure 2.2C is more realistic because it takes into
account the DSC-derived Cp value.39, 53 This curved Gglob profile will serve as starting
point for the analysis of T-dependent HDX-MS data.
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Figure 2.2 Thermal unfolding of 5 M Mb studied by CD spectroscopy. (A) CD spectra
acquired at various temperatures, displaying mean residue ellipticity (MRE) vs.
wavelength. (B) Unfolding profile monitored at 222 nm, heating rate 1 C min-1. Black
symbols are experimental data, colored lines represent fits for two different values of Cp.
(C) Free energy Gglob(T) of the N  U equilibrium according to equation 2.3 and 2.4;
parameters were extracted from the fits of panel B.
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2.3.2

Temperature- and Time-Dependent HDX Experiments

Figures 2.3A and 2.3B exemplify peptide isotope distributions acquired after exposing Mb
to D2O for different times at T = 296 K (23 C). With increasing t the spectra shifted to
higher m/z because of backbone deuteration. A complementary perspective was obtained
by conducting HDX in a T-dependent fashion between 273 K and 353 K, while keeping
the labeling time t constant. We chose t = 30 s, which resulted in a wide dynamic range of
%D value. Mass spectra measured in this way demonstrate that increased T dramatically
enhances the extent of deuteration (Figure 2.3C). In fact, the T-induced spectral changes
were much larger than those seen in the t-dependent data of Figure 2.3A and 2.3B.
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Figure 2.3 HDX-MS isotope distributions of selected peptic peptides. (A) Data acquired
after different labeling time intervals t at a constant temperature of T = 296 K (23 C). (B)
Same as in panel A, but for T = 333 K (60 C). (C) Data acquired at different temperatures
T for a constant labeling time of t = 30 s. Vertical dashed lines indicate centroid m/z values.
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T-dependent %D profiles revealed interesting differences for the various Mb regions
(Figure 2.4). Many of the profiles showed very shallow slopes between 273 K and ~340 K,
e.g., 30-40 and 111-126. These shallow slopes are surprising, considering that kch increases
quasi-exponentially with T.18 Several profiles had an upwards kink at 348 K. This feature
is most pronounced for 111-126, but it also affects 12-20, 21-29, 30-40, 56-69, 87-106, and
124-134. Figure 2.13 summarizes all T- and t-dependent data, including peptides not shown
in Figure 2.4.

Figure 2.4 (A) Deuteration percentage %D as a function of temperature T for a labeling
time of t = 30 s. The sequence range of each peptide is indicated. Pink symbols represent
experimental data, black lines are fits based on equation 2.10. (B) Locations of panel A
peptides in the Mb crystal structure. The cartoon also highlights the eight -helices A-H.
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2.3.3

Developing a Temperature-Dependent HDX-MS Model

We now examine how T-dependent changes in labeling chemistry and protein dynamics
manifest themselves in the HDX behavior, ultimately yielding a model that accounts for
all the experimental data. The deuteration behavior of a peptide with N non-proline residues
covering amino acids k to (k+N-1) can be described as54-56

% ( , )=

1
( − 2)

[ 1 − exp −
(

,

( ) ×

]

)

Equation 2.6
where kHDX,i(T) is the HDX rate constant of NH i. Summation starts at k+2 because the first
two residues undergo complete back exchange during LC.18,

35, 57

Layer by layer, the

following sections describe a strategy to capture the behavior of kHDX,i(T) in equation 2.6
(Figure 2.5). We were guided by the tenets that a good model will (i) be able to
quantitatively match the experimental data, (ii) be as simple as possible, and (iii) have a
minimum number of adjustable parameters.
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Figure 2.5 Layer-by-layer development of a model for interpreting HDX-MS data recorded
as a function of temperature T and labeling time t. Circles represent experimental %D(T, t)
data for peptides 1-7 and 21-29. Note how the quality of the fits improves for A  K/N and
C  O/R. For Layers 1and 2, see text. Layer 3: Global dynamics with and without GopU.
Layer 4: Inclusion of simple local dynamics. Layer 5: Inclusion of local dynamics where each
peptide was dissected into two segments that undergo independent opening/closing. Layer 5
parameters for Peptide 1-7: GopU(3-4) = 0, Hloc(3-4) = -38, Sloc(3-4) = -174, GopU(5-7)
= 0, Hloc(5-7) = 33, Sloc(5-7) = 43. For Peptide 21-29: GopU(23-25) = 20, Hloc(23-25)
= -23, Sloc(23-25) = -143, GopU(26-29) = 22, Hloc(26-29) = 20, Sloc(26-29) = -44 (GopU
and Hloc in kJ mol-1; Sloc in J mol-1 K-1).
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2.3.3.1

Layer 1: Temperature Dependence of kch.

Before focusing on protein dynamics, we examine the chemical rate constant kch that
governs the deuteration of NHopen (equation 2.1). kch depends on T, pD, and neighboring
side chains.18, 58 Its T-dependence is often described using the Arrhenius expression18

( )=

× exp ( −

(

− [298 ] ) )
Equation 2.7a

where kch_298 is a reference value for 298 K, and the effective activation energy Ea_eff is 71.1
kJ mol-1 (Figures 2.6, 2.7).58 However, equation 2.7a is only an approximation.18 The actual
Ea for chemical exchange is 12.6 kJ mol-1.18 The T-dependence of kch arises largely from
changes in [OD-] as governed by the T-dependent ionization constant KD2O = [D+][OD-],32
keeping in mind that HDX in near-neutral solution is OD- catalyzed.33 The analyses below
use the more accurate expression

( )=

_

× exp −

(

− [298 ] ) × [

]( )

Equation 2.7b
with the reference value kB_298 for base-catalyzed exchange (Figure 2.7).18 Between 0 C
and ~60 C the kch(T) profiles predicted by equations 2.7a and 2.7b are similar. At 80 C
the equation 2.7a value is 34% larger than that of equation 2.7b; at higher T the differences
become more pronounced (Figure 2.7).
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Figure 2.6. Temperature dependence of backbone amide H-bond opening/closing, and its
relationship to the temperature dependence of kch. (A) Transition state theory model of the
NHclosed  NHopen equilibrium.48, 59 G#op and G#cl are the activation barrier heights for
opening and closing, respectively. The corresponding rate constants are
#

=

(−

)

=

(−

#

)

(k = Boltzmann constant, h = Planck constant, R = gas constant, T = temperature, and 
= transmission coefficient). The activation free energies can be dissected into enthalpic
and entropic contributions according to G# = H# - TS#, such that
Figure 2.6 Caption (continued):
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=
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)

#

#

)

)

When expressed in this way, it becomes clear that the temperature dependence of kop and
kcl is governed by the activation enthalpies H#op and H#cl, while the entropy terms can
be incorporated into the T-independent prefactor. Heat is required to dissociate H-bonds
(Hop > 0). This implies H#op > H#cl as illustrated in (B), causing kop to depend more
strongly on temperature than kcl.
Panel (C) illustrates how kop and kcl change with temperature. The numerical parameters
were chosen to resemble the global Mb unfolding data of Figure 2.2, i.e., Hop = 453 kJ
mol-1 and H#cl = 100 kJ mol-1 (estimated from literature data60, 61) such that H#op =
553 kJ mol-1. Ccl was arbitrarily chosen as 1018 s-1 K-1 to ensure EX2 conditions with kcl
= 20 s-1 at 273 K. This determines the value of Cop = 3  1084 s-1 K-1 to ensure that kop =
kcl at Tm = 356 K.

Also included in (C) is a temperature-dependent kch profile, calculated using the Arrhenius
parameters of ref.18 for poly-alanine at pD = 7.6 (equation 2.8a).
Key conclusion from the data presented in this Figure: A protein that exhibits EX2 behavior
(kcl >> kch) at low temperature is likely to remain in the EX2 regime when the temperature
is raised. This is illustrated by in panel (C), where kcl remains at least two orders of
magnitude above kch throughout the entire range from 273 K to 373 K.
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Figure 2.7. kch,i values for backbone NH sites along the Mb sequence, for pD 7.6 and 298
K. These values were calculated using Excel files from the Englander Laboratory
(http://hx2.med.upenn.edu/download.html).58

57

2.3.3.2

Layer 2: Verifying the EX2 Regime

The interpretation of HDX-MS data requires different approaches, depending on whether
deuteration proceeds in the EX1 or in the EX2 regime.5, 8-15 EX2, defined as kcl >> kch
(equation 2.1), represents the most common scenario; it is associated with unimodal isotope
distribution that gradually shift to higher mass.2, 12, 19, 20 EX1 (kcl << kch) is less common.
Cooperative EX1 dynamics cause bimodal isotope distributions.12,

19, 20

The unimodal

nature of the spectra in this work confirms that HDX proceeds in the EX2 regime (Figure
2.3). Skeptics might bring up an interesting issue in this context. Because kch increases with
T,18 heating might cause a transition from EX2 (kcl >> kch) at low T to EX1 (kcl << kch) at
high T. However, such an EX2  EX1 transition is unlikely, because kcl and kch both
increase with T (Figure 2.8). We conclude that equation 2.2, which represents the central
paradigm of the EX2 regime, represents a reasonable foundation for analyzing the HDX
behavior of Mb.
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Figure 2.8. (A) Temperature dependence of kch, calculated using the simple Arrhenius
expression of equation 2.8a (main text), and by explicitly taking into account how [OD-]
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in mind that the phosphate-buffered solutions used of the current work are stable against
T-induced changes.46 The data shown here are for poly-alanine with kch(298 K) = 15 s-1.18,
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(B) Concentration of OD- vs. temperature, calculated as follows:
The ionization constant of D2O is

KD2O(T) = [D+]  [OD-](T)

such that

pOD(T) = -log(KD2O(T)) – pD

or

pOD(T) = -log(g(T)/RT) – pD

The OD- concentration (M) is thus given by [OD-](T) = 10-pOD(T)
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(C) g(T) is the free energy change associated with the D2O  D+ + OD- equilibrium.32

g(T) is required for calculating [OD-](T).
g(T) = h(T) - Ts(T)
with the enthalpy

h(T) = h(298 K) + cp (T - 298 K)

and the entropy

s(T) = s(298 K) + cp ln(T/298 K)

where h(298 K) = 59.8 kJ mol-1, s(298 K) = -85.5 J mol-1 K-1, and cp = -229.3 J mol-1
K-1. These parameters imply that kB_298 = 3.45  108 in equation 2.8b, to ensure that kch(298
K) = 15 s-1.
Here we use lower case symbols for solvent-related thermodynamic parameters, whereas
upper case symbols refer to the protein.

Individual NH sites exhibit single-exponential EX2 kinetics only if the NHopen population
in equation 2.1 is small (kcl >> kop).2, 17 To ensure that this criterion is being met, our
analysis will not consider data beyond 353 K (80 C) where the population of U reaches
~22% (Figure 2.5). In the next few paragraphs will use two peptides, 1-7 and 21-29, to
illustrate the remaining layers of the model (Figure 2.4).
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2.3.3.3

Layer 3: Protein Dynamics at High Temperature (Close to
353 K).

There is some uncertainty regarding the exact nature of the opening/closing fluctuations in
equation 2.1.62, 63 As a starting point we try to equate these fluctuations with global N 
U transitions such that equation 2.2 turns into

kHDX,i(T) = exp[ -Gglob(T)/RT ]  kch,i(T)
Equation 2.8a
where Gglob(T) is the free energy derived from CD melting data (Figure 2.2C). Figure
2.5A-D compares the predictions of equation 2.8a with experimental %D(T, 30 s) data for
peptides 1-7 and 21-29. We ignore, for now, the mismatch at low T and focus on higher
temperatures. For peptide 1-7 the equation 2.8a prediction agrees well with experiments
for T  338 K, where %D approaches 100% (Figure 2.5A). In contrast, peptide 21-29 shows
major discrepancies at high T, with experimental %D values that are much lower than
predicted by equation 2.8a (dotted line in Figure 2.5C).
The high-temperature mismatch in Figure 2.5C implies that the unfolded state in the CDdetected N  U equilibrium retains some HDX protection for peptide 21-29. This
interpretation is consistent with reports of residual structure in many other unfolded
proteins,64, 65 which causes NH sites to exchange slower than in dipeptides.57, 58, 66 In other
words, HDX for peptide 21-29 must involve a two-step opening process (N  Ucl  Uop),
where the first step corresponds to the CD-detected Gglob(T). In the context of equation
2.1, Ucl represents a “closed” (exchange-incompetent) state. The subsequent Ucl  Uop
transition generates the HDX-competent “open” state, and this opening event is associated
with an additional free energy GopU. Overall, the N  Uop equilibrium thus has a free
energy of
G*glob(T) = Gglob(T) + GopU
Equation 2.8b
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(Figure 2.5D). For peptide 21-29, GopU = 22 kJ mol-1 generates a HDX profile that agrees
quite well with the experimental data above 348 K (solid in Figure 2.5C). In summary, we
account for residual protection of heat-unfolded Mb by modifying equation 2.7a according
to

kHDX,i(T) = exp[ -G*glob(T)/RT ]  kch,i(T)
Equation 2.8c
where G*glob(T) is defined in equation 2.8b and GopU  0 represents a fitting parameter.
U segments without residual protection have GopU = 0 (such as 1-7, Figure 2.5B). In
principle, GopU will depend on T as expressed in equation 2.4. However, GopU makes its
presence felt only in a narrow range close to Tm, such that the H and S components of
GopU cannot be determined. To avoid the use of such ill-defined parameters, we will
therefore assume that GopU is T-independent.

2.3.3.4

Layer 4: Local Fluctuations.

The Layer 3 considerations refer to relatively high temperatures (around 353 K) where
global unfolding/refolding starts to make its presence felt.34 At lower T global dynamics
are less prevalent, and HDX occurs mainly via local fluctuations.2, 63 Englander et al.2
suggested that the interplay of local and global dynamics can be captured by replacing Kop
in equation 2.2 with the sum Kop(local) + Kop(global). We build on this idea by expanding
equation 2.2 according to

kHDX,i(T) = [ Kop_loc(T) + K*op_glob(T) ]  kch,i(T)
Equation 2.9
The equilibrium constant Kop_loc in equation 2.9 describes local opening/closing
fluctuations which are associated with the free energy Gloc(T), such that Kop_loc = exp[ -
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Gloc(T)/RT ] with Gloc(T) = Hloc - TSloc. To avoid “overfitting”, we make the
approximation that these local events have Cp = 0. As discussed in Layer 3, K*op_glob =
exp[ -G*glob(T)/RT ] describes the N  Uop equilibrium. Equation 2.9 expresses the idea2
that any NH site can reach an open state via two types of dynamics, such that kHDX is the
sum of both kinetic channels. When putting it all together, equation 2.9 turns into

kHDX,i(T) = ( exp[ -(Hloc - TSloc)/RT ] + exp[ -(Gglob(T) + GopU)/RT ] )  kch,i(T)
Equation 2.10
Fitting of the adjustable parameters (GopU, Hloc, and Sloc) results in greatly improved
agreement with the experimental %D(T, 30 s) profiles for both test peptides (Figure 2.5E
and H). Here we assumed that all NH sites in any given peptide share the same
thermodynamic parameters, a limitation that will be improved upon in the following
section.

2.3.3.5

Layer 5: Inclusion of time-Dependent Data.

For extending our model to labeling times beyond t = 30 s we included data at t = 600 s
and 6000 s at 296 K and 333 K. These temperatures were chosen because they provided
%D(T, t) values that covered a wide dynamic range. The inclusion of these additional time
points provides much more stringent constraints for the model parameters.
Layer 4 provides a poor description of the HDX data for t > 30 s (Figure 2.5G, J). Luckily,
a minor modification is sufficient to remedy this mismatch. So far, we assumed that all NH
sites in a peptide share the same GopU, Hloc, Sloc. We now eliminate this unrealistic
restriction. In principle each NH site should have its own GopU, Hloc, and Sloc. However,
such an approach would imply an unrealistically large number of fitting parameters (~148
 3 = 444), generating a mathematically underdetermined situation. To avoid this problem,
we chose a compromise where each peptide was divided into segments. NH sites in each
segment share the same GopU, Hloc, Sloc. This segmentation concept is borrowed from
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the widely accepted foldon model,2 where groups of adjacent NH sites open/close with the
same thermodynamic parameters. In Figure 2.5 we dissected peptides into two segments,
e.g., peptide 1-7 was divided into segments 3-4 and 5-7. Residues 1-2 were not considered
because of back exchange.18, 35, 57 After this modification, equation 2.10 provided excellent
agreement with the experimental data for all T and t (Figures 2.5K/N and O/R).

2.3.3.6

Layer 6: Global Fitting

Many Mb regions were covered by overlapping peptides. Rather than fit each peptide
individually (as in Layer 5), this overlap allows the implementation of a global fitting
strategy (Note: this term refers to a data analysis method;55, 56, 67-69 it is unrelated to “global”
unfolding). Segments that are shared across multiple peptides were modeled using the same
GopU, Hloc, Sloc. Global fitting improves the robustness and accuracy of results
compared to single-curve analyses, and it reduces the number of parameters.55, 56, 67-69 The
22 peptides with the highest S/N were subjected to global fitting (Figure 2.9) by minimizing
=∑

∑ ∑ (%

−%

)
Equation 2.11

where the summation includes multiple peptides, T, and t values. %Dexp refers to
experimental data. %Dcalc values were calculated using equation 2.10. Preliminary segment
boundaries were first determined by analyzing one peptide at a time. If treating a peptide
as a single segment did not yield an acceptable fit, it was divided into two, then three
segments, etc. For global fitting these preliminary boundaries had to be slightly adjusted to
ensure consistency across overlapping peptides. In the end, Mb was dissected into 44
segments, each of which had its own GopU, Hloc, Sloc (44  3 = 132 parameters, segment
boundaries are denoted as vertical lines in Figure 2.9).
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Figure 2.9. Overlapping peptides (red) used for global fitting, illustrating Layer 6 of the
modeling strategy developed here. Blue vertical segments share the same GopU, Hloc,
and Sloc across different peptides; the residue range for each segment is indicated. The
first two residues of each peptide (gray) were not considered due to back exchange.
Preliminary segment boundaries were first determined by analyzing one peptide at a time.
If treating the peptides as a single segment did not yield an acceptable fit, it was divided
into two, then three segments, etc. For global fitting these preliminary boundaries had to
be slightly adjusted to ensure consistency across overlapping peptides (vertical lines in the
figure above).

2.3.3.7

Discussion of Global Fitting Strategy

Global fitting generally improves the robustness and accuracy of parameters compared to
single-curve analyses. At the same time, the number of parameters required for describing
the whole data set is reduced.55,

56, 67-69

The procedure used in our work involved 22

peptides that were dissected into 44 segments, for a total of 44  3 = 132 fitting parameters.
One can contrast this to traditional HDX-MS strategies that use expressions such as

%D = a0 + a1(1-exp[-kapp_1  t] ) + a2( 1-exp[-kapp_2  t] )
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Equation 2.12
with five parameters per peptide (or more, when using additional exponentials).25, 54 For 22
peptides and two temperatures that traditional method would require a minimum of 22  2
 5 = 220 parameters. Here we probed the HDX properties of Mb at eleven (not two)
temperatures. In other words, the number of fitting parameters in our global analysis is low,
compared to traditionally used approaches. More importantly, the parameters obtained here
(GopU, Hloc, and Sloc) directly report on first-principle protein properties. This is in
contrast to the ai and kapp_i values of the equation above, which are difficult to interpret in
a structural/thermodynamic context.

2.3.3.8

Applying the Model to Experimental HDX Data.

HDX-MS data for Mb acquired as a function of T and t were analyzed using equation 2.10.
Gratifyingly, our model produced excellent fits for all 22 peptides, illustrated in Figure
2.4A for selected %D(T, 30 s) profiles. Fitted GopU, Hloc, Sloc parameters are compiled
in Figure 2.10.
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Figure 2.10. GopU, Hloc, and Sloc determined by global fitting of temperature- and timedependent HDX-MS data for 44 segments along the Mb sequence. Shown at the top is the
Mb secondary structure with helices A-H. Plots of Gglob*(T) and Gloc(T) derived from
the parameters shown here are summarized in Figure 2.11. Errors bars indicate by how
much each value could be altered to cause a 10% increase of X2. Asterisks highlight two
segments that are further examined in Figure 2.12.
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Figure 2.11. HDX-MS isotope distributions of selected peptic peptides. (A) Data acquired
after different labeling time intervals t at a constant temperature of T = 296 K (23 C). (B)
Same as in panel A, but for T = 333 K (60 C). (C) Data acquired at different temperatures
T for a constant labeling time of t = 30 s. Vertical dashed lines indicate centroid m/z values.
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GopU Values. Consistent with previous observations,57, 58, 64-66 our data show that the CDdetected globally unfolded state retains residual protection. Deuteration of Ucl is mediated
by opening/closing transitions with a free energy GopU. Most of the fitted GopU values
fell in the range of 20 to 40 kJ mol-1 (Figure 2.10A). The similarity of GopU across much
of the protein could suggest the occurrence of cooperative Ucl  Uop fluctuations.2
However, the presence of independently fluctuating segments cannot be ruled out.
Hloc and Sloc Values. Before examining the remaining fitting parameters, we note that
N  U equilibria can follow different thermodynamic scenarios. (i) Unfolding is often
endothermic (H > 0) because energy is required to dissociate contacts within the protein
that stabilize N (e.g., H-bonds). Under these conditions the enhanced conformational
freedom of U usually results in S > 0.38, 39 In the context of global Mb unfolding this
scenario applies for T > 303 K, where the slope of Gglob(T) is negative (Figure 2.5B). (ii)
N  U equilibria can also be exothermic (H < 0) with S < 0,39, 70 as seen in Figure 2.5B
for T < 303 K where Gglob(T) has a positive slope. The origin of this second scenario
remains poorly understood,41 but the assembly of tightly H-bonded shell water around
unfolded regions likely plays a role.71
The aforementioned two scenarios are well established for global N  U equilibria.39, 70,
71

It is reasonable to assume that these concepts also extend to local closed  open

fluctuations. Consistent with this expectation, our HDX fits yielded positive as well as
negative Hloc and Sloc values (Figure 2.10B, C). Segments with Hloc > 0 and Sloc > 0
were located mostly within long helices (such as B, G, and H), corresponding to scenario
(i) described above. Conversely, most segments with Hloc < 0 and Sloc < 0 (scenario ii)
were found at helix/loop boundaries (Figure 2.10B, C). This spatial distribution is
intriguing, but from the data presented here it cannot be decided why these specific regions
follow one scenario versus the other.
Interplay of Local and Global Dynamics. It is gratifying that equation 2.10 can capture
the entire HDX-MS data set for different T and t. We will illustrate the underlying Tdependent local and global dynamics for two residues, L32 and G124 (Figure 2.12); these
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were selected because of their particularly large |Hloc| and |Sloc| (asterisks in Figure
2.10B, C).

Figure 2.12. Temperature-dependent HDX events, illustrated for the backbone NH sites of
L32 (left) and G124 (right). (A, F) Free energy profiles for local and global fluctuations,
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Figure 2.12 Caption (continued):
calculated from GopU, Hloc, and Sloc parameters of Figure 2.10. (B, G) Conversion of
free energy to equilibrium constants, along with their sum (red lines, eq. 8). (C, H) kch,32
and kch,124, calculated using eq. 6b. (D, I) kHDX,32 and kHDX,124, calculated as the product of
“Sum” in panels B/G, and kch in panels C/H (eq. 8). (E, J) %D for a labeling time of 30 s.
Note that except for A/F, all panels have logarithmic y-axes.

The HDX behavior of any NH site is governed by the opening/closing fluctuation with the
lowest G (the largest Kop).2 Accordingly, HDX of L32 is dominated by local fluctuations
throughout the entire T range, while global events are negligible (Figure 2.12A, B). As
expressed in equation 2.9, multiplication of the Kop “Sum” (red line in Figure 2.12B) with
kch (Figure 2.12C) yields kHDX (Figure 2.12D). The resulting %D(T) profile increases
toward 100% in a near-exponential fashion (Figure 2.12E). This steep %D(T) rise results
from three effects: 1. kHDX increases with T (Figure 2.12D). 2. The exp(-T-1) dependence in
equation 2.10 favors open conformations at high T. 3. Gloc(T) has a negative slope (Sloc
> 0) which further promotes the open state at high T (Figure 2.12A).
The experimental %D(T, 30 s) profiles of many Mb peptides had very shallows slopes at
low T, followed by a sudden increase close to Tm (e.g. peptide 111-126 in Figure 2.4A). It
would be impossible to model these data if all NH sites had rapidly increasing %D profiles
similar to that of Figure 2.12E. A look at G124 reveals how our model solves this problem.
G124 has Sloc < 0, resulting in a positive slope for Gloc that suppresses local opening
with increasing T. At 343 K the Gloc and G*glob curves intersect; beyond this temperature
HDX takes place mainly via global dynamics (Figure 2.12F). As a result, kHDX(T) decreases
slightly between 273 K and 343 K, followed by a sudden upward kink (Figure 2.12I). This
behavior is echoed in the %D(T, 30 s) profile of Figure 2.12J as well as the experimental
data of peptide 111-126 (Figure 2.4A).
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In summary, Mb dynamics at low T are dominated by local fluctuations. For some of these
local fluctuations Gloc(T) decreases, while for others Gloc(T) increases with T. The latter
account for the very shallow slopes that were experimentally observed for many %D(T)
profiles at low T. The conspicuous kink of the experimental %D(T) data at around 343 K
results from a crossover of Gloc(T) and Gglob(T), marking the point at which global
fluctuations start to dominate.
Figure 2.13 summarizes all T- and t-dependent data, including peptides not shown in Figure
2.4.
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Figure 2.13. Complete experimental HDX-MS data set (colored dots), with fits (black
lines) based on equation 2.11 obtained by global analysis of overlapping peptides.

2.4

Conclusions

For the first time, the current work provides a thermodynamic model that can quantitatively
describe temperature-dependent protein HDX-MS data. For conventional time-dependent
HDX-MS experiments it is common to use multi-exponential fits with apparent rate
constants.54 Unfortunately, that conventional approach only yields a phenomenological
description of the data, and the fitting parameters obtained are difficult to interpret in a
structural/thermodynamic context. This is in contrast to the temperature-dependent model
developed here, where the fitting parameters directly report on first-principle protein
properties (GopU, Hloc, and Sloc).
The analysis strategy presented here captures the interplay of local fluctuations (which
dominate at low T) and global unfolding/refolding (which becomes prevalent closer to Tm).
Some of the local fluctuations are associated with Hloc > 0 and Sloc > 0, representing the
canonical scenario38,

39

where thermal energy is required to disrupt local noncovalent
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contacts, and where locally unfolded segments are more disordered than in the native state.
On the other hand, there are also local events with Hloc < 0 and Sloc < 0. The structural
origin of this second scenario remains to be fully elucidated, but it may be caused by tightly
H-bonded water around the locally unfolded regions.39,

70, 71

The second scenario is

indispensable for modeling the shallow slopes seen for many of the experimental HDX
profiles at low temperature. Another essential ingredient of our model is residual HDX
protection of the globally unfolded state, implying that U undergoes transient opening
transitions that are associated with GopU. This phenomenon is consistent with studies on
many other proteins.57, 58, 64-66
This work provides practitioners with a tool for analyzing HDX-MS data across a
wide range of temperatures, e.g., for assessing the thermal stability of protein
therapeutics.15, 30, 31 The key steps required for applying this method are as follows: (i)
Ensure that the protein does not aggregate in the T range of interest. (ii) Determine global
unfolding parameters (Tm, Hglob(Tm), Cp) by CD spectroscopy, DSC, or from the
literature. (iii) Measure %D for overlapping peptides over a wide temperature range and at
different time points and verify EX2 behavior. (iv) Perform global fitting on the basis of
equation 2.10.
An interesting aspect of temperature-dependent HDX-MS is the dramatically shortened
time scale. Traditional room temperature assays routinely employ labeling times up to
many hours,5, 8-15 whereas the current work demonstrates that complete HDX profiles can
be generated in as little as 30 s (Figure 2.4A). With robotic technology it should be possible
to develop temperature-dependent HDX-MS workflows for high-throughput applications
such as excipient screening30 or drug candidate binding tests.11 In any case, it is hoped that
the current work will encourage practitioners to explore the use of temperature-dependent
HDX-MS, instead of being confined to traditional time-domain measurements.
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3

Chapter 3. Mechanism of Thermal Protein Aggregation:
Experiments and Molecular Dynamics Simulations on
the High Temperature Behavior of Myoglobin

3.1

Introduction

The native conformations of typical globular proteins are tightly folded. These proteins
possess a hydrophobic core, while the exterior is dominated by charged and polar side
chains that interact favorably with water.1 In addition to the hydrophobic effect, native
proteins are stabilized by H-bonds, van der Waals contacts, salt bridges, and (sometimes)
disulfide bonds.2,

3

Unfolding can be triggered by exposure to non-physiological

temperatures, extremes of pH, or chemical denaturants.4-6 Many unfolding transitions show
two-state behavior (N  U),7-10 although partially folded intermediates can become
populated for some proteins.11-13
Protein aggregation is an enigmatic phenomenon that is closely intertwined with the
question how proteins fold and unfold.14, 15 Aggregation refers to the assembly of proteins
into non-native higher-order structures. The widespread interest in protein aggregates is
based on their involvement in various diseases, including Alzheimer’s and Parkinson’s,
ALS, and many others.16-21 Also, aggregation can limit the shelf life and efficacy of protein
therapeutics such as monoclonal antibodies.22 Aggregates of such protein therapeutics have
been linked to adverse immune responses.23 Understanding the mechanisms of protein
aggregation in vitro and in vivo, therefore, is of great interest for a wide range of
applications.
Protein aggregates come in many shapes and sizes.14, 16 Their heterogeneous and disordered
nature usually precludes the application of high-resolution structure determination
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methods. Even the use of standard spectroscopic tools (such as CD spectroscopy) is
challenging due to light scattering and solubility issues.24 As a result, the structures of
aggregates and their formation mechanisms remain poorly understood.14,

16, 25

Many

practitioners will have witnessed aggregation in samples that were unstable. Such
aggregates tend to be amorphous, and micrometer sized, causing Rayleigh scattering that
gives the degraded samples a turbid (“cloudy”) appearance.24, 26-28
Amorphous aggregates are insoluble, and they can be collected as a pellet after spinning
the samples in a standard centrifuge.26, 27, 29, 30 Various numerical approaches have been
applied for modeling the formation kinetics of amorphous aggregates.28, 31 Aggregation of
most proteins is based solely on noncovalent contacts.16 The intermolecular clustering of
hydrophobic side chains appears to be highly important in this context,14, 32, 33 sometimes
in combination with H-bonding across intermolecular -sheets.24,

34, 35

Other types of

interactions may participate as well,14 including intermolecular disulfide bridges for Cyscontaining proteins.36, 37 Amyloid fibrils are a special type of aggregate that is relatively
ordered and has a cross- structure.16, 38, 39 Although amyloid is associated with numerous
diseases,16 the actual cytotoxic species are likely not full-length fibrils but smaller
oligomers.20, 40-42
Aggregation can be promoted by exposing proteins to destabilizing conditions.43 Heating
is particularly effective in this regard,44-47 especially for solutions that are highly
concentrated.14, 29, 33 In contrast, heating at low concentration favors reversible unfolding
such that thermodynamic parameters can be measured, e.g., by differential scanning
calorimetry (DSC) or in optical experiments.10, 48 Chemical denaturants such as urea and
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guanidinium hydrochloride tend to solubilize non-native chains, such that aggregation is
less prevalent than with heating.24, 49
Two main aggregation mechanisms have been proposed in the literature. Many studies
emphasize the role of partially folded intermediates as aggregate precursors (N  Partially
Folded  Aggregated).16, 17, 45-47, 50, 51 Others envision that aggregation commences from
globally unfolded conformers (N  U  Aggregated).35, 52-55 In either case, aggregates
start out as small soluble complexes that grow into larger insoluble assemblies as more and
more chains associate with the initial nuclei.21, 30, 56 In addition to aggregation in bulk
solution (which is the topic of the current study), there is also the possibility of aggregation
at liquid/vapor interfaces, e.g., in solutions that contain air bubbles.57, 58
Molecular dynamics (MD) simulations have become a key tool for exploring protein
folding and dynamics.59-63 Surprisingly, this technique remains under-utilized when it
comes to protein aggregation, as there are only relatively few MD investigations in this
area. Most of those studies have focused on amyloid formation20, 64-69 using simple coarsegrained force fields with or without explicit solvent.68 Some others explored specific
aspects of aggregation, such as cytotoxic SOD1 oligomers,40 urea effects on short
peptides,70 and cataract formation from crystallin.33 However, there have been very few
attempts to model the formation of amorphous aggregates from common globular proteins
using atomistic MD simulations with explicit solvent.
To enhance the general understanding of protein aggregation, the current work examines
the behavior of myoglobin (Mb) at elevated temperature. Mb is a well suited model for this
purpose, because of its paradigmatic role in earlier studies related to protein structure
determination,71 folding/unfolding,5, 11 thermodynamics,48 conformational fluctuations,72
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and amyloid formation.73 Native Mb has a globular structure that comprises eight helices
(A-H), with a hydrophobic core and a hydrophilic exterior.74 Among its 153 amino acids
there are no Cys residues, eliminating complications related to disulfide bonding. Heating
of Mb triggers the formation of amorphous (i.e., non-amyloid)14 aggregates.24,

35

IR

spectroscopy suggests that these aggregates have partial -sheet structure, and that some
of the -sheets are involved in intermolecular H-bonding.24, 35 Just like for other aggregates,
hydrophobic contacts and other types of interactions likely play a role as well.14, 32, 33
Molecular details of Mb aggregation remain unknown. Here we perform experiments and
atomistic MD simulations in explicit solvent to uncover mechanistic aspects of heatinduced Mb aggregation. We find that aggregation proceeds through the interaction of
globally unfolded chains, and we provide detailed insights of the highly dynamic events
that culminate in the formation of higher order assemblies.

3.2

Methods

H Horse-heart ferri-Mb was from Sigma (St. Louis, MO). Initial stock solutions prepared
at room temperature were centrifuged to remove small amounts of insoluble debris. All
samples contained 50 mM sodium phosphate buffer and 100 mM NaCl in water at neutral
pH. Circular dichroism (CD) data were acquired between 20 °C and 96 °C on a Jasco J810 instrument (Easton, MD) with a 1 mm cuvette using 5 µM Mb. Unfolding profiles
were generated by monitoring the CD signal at 222 nm. These profiles were analyzed using
the expression2, 10
=

(

) (

)
( ∆ ( )/

( ∆ ( )/
)

)
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Equation 3.1
where the free energy of unfolding is G(T) = H(1 – T/Tm), and where Tm denotes the
melting temperature. Following established protocols,10 the enthalpy of unfolding (H)
was assumed to be constant for the temperature range considered here. The (yN + mNT) and
(yU + mUT) terms in equation 3.1 represent the pre- and post-transition baselines,
respectively. From the fitted parameters, the fraction of globally unfolded protein fU can be
calculated as
=

( ∆ ( )/
( ∆ ( )/

)
)

Equation 3.2
Aggregation assays were conducted by immersing Mb samples at concentrations between
5 M and 100 M in a T-controlled water bath for various time intervals (6 s to 100 min).
The samples were then centrifuged (10 min, 13000 g) for precipitate removal, and the
supernatant was analyzed using a Cary 100 spectrophotometer (Varian, Mississauga, ON)
to quantify the leftover soluble Mb at 409 nm. Some of the samples had to be diluted to
ensure absorbance readings < 1.

3.3
3.3.1

Results and Discussion
Thermal Aggregation Experiments.

As an initial step, we characterized the heat-induced aggregation of Mb experimentally,
with the goal of establishing realistic conditions for subsequent MD simulations. Thermal
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aggregation was probed by heating of aqueous Mb solutions, followed by centrifugation
for removal of precipitated aggregates. UV-Vis spectroscopy was then used to quantify the
residual (non-aggregated) protein. Aggregation was negligible for samples that had been
heated for 20 min regardless of protein concentration, as long as the solution temperature
did not exceed 348 K (Figure 3.1A). At higher temperatures aggregation became prevalent,
especially for high concentrations. For example, exposure of 100 M Mb to 358 K for 20
min caused almost complete aggregation (Figure 3.1A). For temperatures above 348 K,
aggregation became more prevalent when the heat exposure time was increased (Figure
3.1B). Overall, the assays of Figure 3.1A,B confirm the expected trends,11,

29

i.e., an

increase of aggregation with increasing temperature, protein concentration, and time.

3.3.2

Relationship between Global Unfolding and Aggregation.

The aforementioned experiments revealed that Mb aggregation can be prevented by using
low protein concentrations (5 M). These conditions were used for unfolding experiments
that monitored changes in -helicity by CD spectroscopy at 222 nm.75 Thermal unfolding
data generated in this way are exemplified in Figure 3.1C. CD melting experiments were
repeated five times at scan rates of 1 K min-1 and 4 K min-1. The profiles obtained in this
way were all very similar. Fits on the basis of equation 3.1 resulted in Tm = 356.2  0.6 K
and H = 450  20 kJ mol-1.
Evidently, equation 3.1 describes the experimental melting profiles very well (Figure
3.1C). This equation is based on a two-state model.10 In other words, our data indicate that
thermally-induced global breakdown of the Mb helical structure can be approximated as a
N → U two-state process. This finding is supported by DSC data,48 and by the results from
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chapter 2 that showed Mb has a melting at ~204 nm isodichroic point that represents a
hallmark of two-state helix → coil transitions. Despite the two-state character of this
transition, IR data reveal that global unfolding is preceded by subtle conformational
changes around 330 K,76 i.e., ~26 K below the global unfolding transition of Figure 3.1C.
Mass spectrometry experiments have attributed this pre-transition to heme loss from the
protein.77
Figure 3.1D compares Mb aggregation with the fraction of globally unfolded protein (fU,
from equation 3.2). Even at the highest concentration, aggregation is negligible up to T =
348 K where the fraction of globally unfolded protein remains close to zero (fU ≈ 3% at
348 K). For higher temperatures fU rises sharply, concomitant with dramatically increased
aggregation. Hence, the aggregation propensity is closely correlated with the fraction of
globally unfolded Mb. In contrast, the aforementioned heme loss at ~330 K is not sufficient
for triggering aggregation. Taken together, these data strongly suggest that thermal
aggregation of Mb proceeds from the globally unfolded state, via a mechanism that can be
expressed (in simplified form) as N  U  Aggregated. IR data on Mb support this
mechanism35 which also seems to be operative for some other proteins.52-54 We do not rule
out that there are proteins that aggregate via partially folded intermediates,16, 17, 45-47, 50, 51
but aggregation of heated Mb appears to result from the interaction of globally unfolded
chains.
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Overall, the experiments of Figure 3.1 identify suitable conditions for the subsequent MD
runs. Accordingly, we performed aggregation simulations on heated proteins that were
completely unfolded, rather than using semi-folded conformations.

Figure 3.1. Mb aggregation monitored by UV-Vis spectroscopy as a function of protein
concentration, temperature, and time. (A) Aggregation after 20 min of heat exposure at
different Mb concentrations. (B) Aggregation of 100 M Mb at different temperatures. (C)
Thermal unfolding of 5 M Mb monitored by CD spectroscopy at 222 nm, with a fit based
on equation 3.1. (D) Colored data represent the fraction of aggregated Mb after 20 min of
heat exposure at different protein concentrations. Also shown in panel D is the fraction of
unfolded protein (fU), deduced from the CD data via equation 3.2
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3.3.3

Overview of Aggregation MD Data

All simulations were performed at 370 K, in accordance with the experiments of Figure
3.1 which demonstrated that aggregation was most pronounced at the highest temperatures.
Snapshots for one of these runs are shown in Figure 3.2, illustrating the association of two
thermally unfolded monomers into a dimer, with subsequent trimer, tetramer, and pentamer
formation. The association time required for newly added monomers was variable, ranging
from tens to hundreds of nanoseconds. The protein backbone in the pentameric aggregates
was mostly coiled, although there were a few short -helical and -sheet segments.
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Figure 3.2. MD simulation snapshots, illustrating the stepwise assembly of a pentameric
Mb aggregate from thermally unfolded monomers. Each monomer is shown in a different
color. Panels on the right show the structures of aggregated complexes, just prior to
addition of a new monomer into the simulation box. The cumulative simulation time is
indicated in each frame. These MD data were generated by Yuen Ki Ng, with the help of
Pablo M. Scrosati. 78
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3.3.4

Conclusions

The in vitro aggregation of heat-unfolded proteins such as Mb ultimately produces
micrometer sized (or even larger) amorphous assemblies.24, 26, 27 Unfortunately, such large
systems are beyond the size range that is accessible to atomistic MD simulations. The
current work for the first time provides detailed in silico insights into the initial steps of
these assembly processes, from heat-unfolded monomers to pentameric aggregates. The
assembly mode pursued in our MD runs, where aggregates grow via attachment of
monomers, will dominate the early stages of aggregation because monomers are the most
abundant solution species early during the reaction. Growth via monomer attachment may
continue even for larger assemblies, as proposed for A fibrils68, 79 and other types of
aggregates.21 An alternative scenario for the Mb system studied here is that large
aggregates arise from binding of smaller oligomers to one another.
It is tempting to speculate on the implications of our findings for the aggregation of other
small, single-domain proteins. The experiments of Figure 1 imply that Mb and some other
proteins35, 52-55 aggregate via globally unfolded chains (N  U  Aggregated). This view
contrasts reports that emphasize the role of partially folded species (N  Partially Folded
 Aggregated).16, 17, 45-47, 50, 51 It is possible that both models are adequate, and that the
mechanisms are protein specific. Alternatively, global unfolding may play a more central
role than previously thought, i.e., formation of U could be an obligatory step for
aggregation of most proteins. In other words, we speculate that even proteins with
purported “aggregation-prone” semi-folded species might follow a mechanism such as N
 Partially Folded  U  Aggregated. Support for this idea comes from the fact that
conditions favoring partially folded structures will also give the globally unfolded state a
relatively high Boltzmann weight.80 We reiterate that these considerations apply to small,
single-domain proteins. The situation is likely different for larger systems such as IgGs,
where individual domains unfold sequentially, and where unfolding of one domain may be
sufficient for triggering aggregation.81, 82 It is hoped that future studies will shed additional
light on these and other questions related to protein dynamics and aggregation. The
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computational strategies devised in the current work seem well suited for tackling many of
these issues.
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4

Chapter 4. Structural Dynamics of a Thermally Stressed
Monoclonal Antibody Characterized by TemperatureDependent H/D Exchange Mass Spectrometry

4.1

Introduction

Protein therapeutics play an ever-increasing role in medicine.1-3 Above all, monoclonal
antibodies (mAbs) and mAb-derived antibody-drug conjugates (ADCs) of the IgG1
subclass have had a major impact for treatment of cancer, as well as infectious and
autoimmune diseases.4-7 IgG1 proteins consist of two identical heavy chains and two
identical light chains that are linked by disulfide bonds. Each heavy chain has one variable
domain (VH) and three constant domains (CH1, CH2, CH3). Both light chains have one
variable (VL) and one constant domain (CL). Each of the two Fab arms comprises CH1
and CL, along with VH and VL which form the Fv moiety that is responsible for antigen
binding. The Fc substructure consists of CH2/CH2’ and CH3/CH3’ domains, the former
being decorated with N-linked glycans (Figure 4.1A).7-9
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Figure 4.1. (A) Cartoon representation of an IgG1 mAb. Disulfides are represented as
dashed orange lines, “G” indicates glycans. (B) Structure of NSTmAb, using the same
coloring as in panel A.10 Disulfide-linked Cys residues are shown in orange, glycans are
shown as pink sticks. The Fab moieties have 2 × 431 residues, CH2 and CH3 have 2 × 118
and 2 × 109 residues, respectively.

Protein therapeutic formulations are required to survive for at least two years in solution at
4 °C without aggregation, chemical modification, or surface adsorption.10, 11 Excipients can
help suppress such degradation events. Unfortunately, laborious screening is required to
identify suitable conditions for each new product.11, 12 Monitoring the stability of proteins
in real time (years) is incompatible with an efficient product development pipeline.
Accelerated screening assays address this issue by exposing proteins to unfavorable
thermal, mechanical, or pH environments.11-14 Thermal stability assays are particularly
important, based on the premise that proteins with a high melting temperature (Tm) usually
degrade more slowly during long-term storage.11-15
Differential scanning calorimetry (DSC) is widely used for assessing the thermal stability
of mAbs and other protein therapeutics.7, 12, 15-17 For two-state unfolding of the native state
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to the unfolded state, DSC thermograms show a single peak at Tm. The peak area represents
the enthalpy of global unfolding (ΔHglob > 0).18, 19 Thermodynamic analyses require that
unfolding is reversible.18, 19 Unfortunately, this is not the case for mAbs, which undergo
irreversible aggregation after thermal unfolding.7, 17, 20, 21 DSC profiles of mAbs are further
complicated by the presence of several unfolding transitions that arise from the multidomain architecture of the protein (Figure 4.1A).7, 14, 17, 20-23 Such data can only be analyzed
in a semi-quantitative fashion,18,

19

relying on Tm values as indicators of protein

robustness.7, 14, 17, 20-25
DSC and related techniques report on global unfolding.18, 19, 26, 27 However, proteins also
undergo a wide range of local fluctuations28, 29 that are crucial for biological function30-32
and that may play a role during aggregation.33, 34 A comprehensive characterization of these
dynamics is highly desirable. Hydrogen/deuterium exchange (HDX) mass spectrometry
(MS) has become a key tool in this context,35, 36 specifically for protein therapeutics.3, 12, 25,
37-44

HDX-MS monitors the deuteration of backbone NH sites in D2O. HDX is mediated

by NHclosed ↔ NHopen fluctuations, i.e., transient unfolding events that are associated with
H-bond disruption.45 In the EX2 regime29 HDX proceeds with an overall rate constant

kHDX = Kop  kch

Equation 4.1
where Kop is the NHclosed ↔ NHopen equilibrium constant, and kch is the “chemical” rate
constant.46
Traditional HDX-MS experiments monitor deuteration as a function of time (t) at constant
temperature (T). Keeping in mind the need for investigating thermally stressed proteins,1115

it is an obvious question whether T can serve as additional HDX-MS variable. The key

problem with T-dependent HDX-MS is that both terms in equation 4.1 change with T. It is
therefore unclear to what extent HDX alterations can be ascribed to changes of the protein
(Kop) vs. changes of the labeling chemistry (kch). Only the former is of interest for

102

characterizing protein behavior. With some exceptions,47 earlier T-dependent HDX work
did not clearly separate the two contributions.48-54 Using myoglobin as a model system, we
recently proposed a thermodynamics model to dissect T-dependent HDX-MS data into
Kop(T) and kch(T) contributions (Chapter 2). The key ideas of this strategy are as follows:
Protein dynamics at ambient T are dominated by local fluctuations of the native state,29, 55
whereas global unfolding/refolding becomes prevalent in the vicinity of Tm.19 To capture
the participation of both local and global dynamics, equation 4.1 can be modified to

kHDX(T) = [ Kloc(T) + K*glob(T) ]  kch(T)
Equation 4.2

Kloc(T) refers to local opening, K*glob(T) represents global unfolding and, kch(T) can be
calculated from tabulated data.46, 56, 57 When expressing K values via free energy (ΔG),
equation 4.2 becomes

kHDX(T) = [ exp(-ΔGloc/RT) + exp(-ΔG*glob/RT) ]  kch(T)
Equation 4.3

where local fluctuations are governed by enthalpic (ΔHloc) and entropic (ΔSloc)
contributions

ΔGloc = ΔHloc – T × ΔSloc
Equation 4.4

and global dynamics are determined by the free energy
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ΔG*glob = Gglob(T) + GopU
Equation 4.5
In equation 4.5, Gglob(T) is the free energy of global unfolding that can be measured by
DSC.19 The GopU > 0 term in equation 4.5 accounts for residual protection of the unfolded
state.56, 58-62
The framework outlined above successfully captured the T-dependent HDX behavior of
myoglobin, which represents a relatively simple protein (Chapter 2). In the current work
we explored whether the same strategy can be extended to a much more complicated
system, i.e., a thermally stressed IgG1 mAb. We focused on the NIST monoclonal antibody
(“NISTmAb”, 150 kDa, 2 × 663 residues, Figure 4.1B), a reference system that has been
widely studied using crystallography,63 computational modeling,64 DSC,23, 43 and constanttemperature HDX-MS.39, 43, 65, 66 We found that different regions of NISTmAb displayed
distinct types of T-dependent HDX-MS profiles, reflecting the interplay of local and global
dynamics as well as thermal aggregation. We implemented a global fitting strategy that
captured this T-dependent HDX behavior on the basis of equation 4.1-4.5, yielding detailed
insights into the thermodynamic properties (ΔHloc, ΔSloc, GopU) of individual protein
segments.

4.2
4.2.1

Methods
Experimental Procedure

NISTmAb Reference Material 8671 was purchased form the National Institute of Standards
and Technology.64 All solutions contained 50 mM sodium phosphate buffer and 100 mM
NaCl. DSC data were recorded a MicroCal VP-DSC instrument at a scan rate of 1 °C min1

using a protein concentration 3.3 µM (0.5 mg/ml) at pH 7.0. Analysis of the DSC data

was performed using Microsoft Excel.
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T-dependent HDX experiments were conducted by mixing 66 μM NISTmAb in H2O with
D2O in a 1:9 ratio, producing 10 µL of 6.6 μM protein in 90% D2O. Initial experiments
were performed at a pH meter reading of 7.0, but those conditions caused premature HDX
saturation at elevated temperature (data not shown). To enhance the dynamic range of our
experiments, the data discussed below were recorded using slightly more acidic
solutions,46,

48

i.e., pH meter reading of 6.3 (corresponding to pD 6.7).67 HDX was

performed at 0, 23, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, and 95 °C in Eppendorf tubes
that were immersed in a T-controlled water bath. Prior to HDX, D2O labeling buffer was
pre-equilibrated at the desired temperature, while NISTmAb was kept at room temperature
to avoid aggregation of the stock solution. After different time points (15 s, 30 s, 2 min,
and 20 min) HDX was quenched by 1:1 mixing with 0 °C aqueous solution containing 8
M urea and 1 M tris(2-carboxyethyl) phosphine (TCEP·HCl) at pH 2.3. This was followed
by flash freezing and storage in liquid N2. For analysis, samples were thawed to 0 °C, and
kept on ice for 2 min to allow for TCEP-mediated disulfide reduction.68, 69 The samples
were then diluted by adding 2 volumes of aqueous formic acid (pH 2.3) to prevent pepsin
degradation by TCEP. 60 µL aliquots were injected into an Acquity HDX-UPLC (Waters,
Milford, MA). Digestion was performed on an immobilized pepsin column (Waters) at 15
°C. Peptides were separated on a 1.7 µm BEH130 C18 2.1 × 100 mm2 column using a 20
min water/acetonitrile gradient with 0.2% formic acid at ∼0 °C. To prevent carryover,
blanks were injected, and the pepsin column was washed with 1.5 M guanidine
hydrochloride in water/acetonitrile/formic acid (95.2/4/0.8) after each sample. The UPLC
was coupled to a Waters Synapt G2 electrospray mass spectrometer operated in IMS
mode.70 The identity of each peptide was confirmed by MSE on nondeuterated samples
with data analysis by Waters PLGS 2.5.3, based on the sequence reported in the NIST
Reference Material 8671 Report of Investigation.64 The sequence coverage was 72% and
92% for the light and heavy chains, respectively (Figure 4.7). For quantitative analyses we
only considered peptides with the highest S/N, lowering the coverage to 72% and 76%
(Figure 4.8). Centroid m/z values were determined using Waters DynamX 3.0 and these
were converted to percent deuteration using %D(t, T) = (m - m0)/(m100 - m0) × 100%, where
m is the centroid, while m0 and m100 are minimally and fully deuterated controls,
respectively.71 The former was prepared by adding NISTmAb to prequenched D2O buffer,
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followed by flash freezing. m100 samples were prepared in the same way, except that they
were incubated for 8 h at 55 °C prior to flash freezing. All %D values are averages of two
independent experiments; error bars represent the deviation between these measurements.
Protein aggregation precluded data acquisition for the 20 min time point at the two highest
temperatures (90 and 95 °C).

4.2.2

Data Analysis

The HDX kinetics of peptides with N non-proline residues covering amino acids k to (k+N1) was modeled as72-74

%

( , )=
(

)

∑

)[

(

1 − exp −

,

×

]
Equation 4.6

This equation excludes the first two residues which undergo complete back exchange
during UPLC separation.56 Each kHDX value in equation 4.6 depends on T, ΔGglob, kch, ΔHloc,
ΔSloc, and ΔGopU (equation 4.3). Measuring T is trivial. ΔGglob(T) was determined by DSC,
as discussed in the following section. kch(T) values were calculated for each NH site by
initially determining kch reference values at 298 K.46, 56 Most of these values fell into a
narrow window around an average of 3.1 s-1 (Figures 4.2, 4.3A). Then, kch(T) was obtained
via (chapter 2)

( )=

_

× exp −

(

− [298 ] ) × [

]( )

Equation 4.7
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with46 Ea = 12.6 kJ mol-1, and kB_298 chosen such that kch(298 K) from equation 4.7 matched
the reference values of Figure 4.2. kch(T) profiles generated in this way are exemplified in
Figure 4.3A. Finally, ΔHloc, ΔSloc, and ΔGopU were determined by global least-square fitting
that used in Chapter 2 of the experimental %D(t, T) data by minimizing the expression
=

% ( , )−%

( , )

Equation 4.8

where the summation includes all peptides, temperatures, and time points. %D(t,T) refers
to experimental data, and %Dcalc(t,T) values were calculated using equation 4.6. Additional
details are outlined in Results and Discussion. All peptide isotope distributions used for
our analyses were monomodal, thereby indicating EX2 conditions in accordance with
previous data on NISTmAb.43
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Figure 4.2. kch values of all NH sites in the (A) light chain and (B) heavy chain of NISTmAb
for T = 298 K and pD = 6.7. The data were generated using HXrates2018_HD.xlsx from
the Englander laboratory website.46, 56
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Figure 4.3. (A) Histogram of kch values at 298 K for all NH sites in the heavy and light
chains, from Figure 4.2. The average kch of 3.1 s-1 is indicated by the vertical dashed line.
(B) Temperature dependence of kch for three selected backbone amides, representing the
fastest and the slowest NH sites, as well as one that is close to the average. The data in
panel B were calculated using equation 4.7 (note the logarithmic y-axis).
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4.3
4.3.1

Results and Discussion
DSC Unfolding Experiments

The analysis of T-dependent HDX-MS data requires knowledge of Gglob(T) in equation
4.5, that was applied in Chapter 2. For this reason, we characterized the global unfolding
of NISTmAb by DSC. Uncorrected DSC data exhibited three endothermic maxima that
signify unfolding transitions. These transitions were followed by a drop into the exothermic
range at high T, representing the hallmark of aggregation (Figure 4.4A, black profile). The
presence of amorphous aggregates was also apparent from visual inspection of heated
samples (Figure 4.12). Consistent with earlier work,7, 17, 20, 21, 43 our observations show that
NISTmAb remains soluble up to roughly 85 °C, while for T > 93 °C the protein behavior
is dominated by aggregation and precipitation. We selected data points in these two
temperature regions and interpolated them with a polynomial, yielding a background
profile that approximates the aggregation contributions to the thermogram (Figure 4.4A,
pink symbols and line). Subtraction of this background from the raw data yielded a
corrected thermogram that reports on the thermal unfolding of NISTmAb (Figure 4.4B,
black solid line).
The baseline-corrected thermogram was deconvoluted into Gaussians using least-square
fitting (Figure 4.4B). Melting points determined from Gaussian maxima were Tm1 = 344.4
K, Tm2 = 357.0 K, and Tm3 = 362.7 K, in close agreement with previous work.23,

43

Regardless of IgG1 sequence, CH2 has the lowest stability,7, 14, 75 while Fab unfolding is
associated with the tallest signal in the thermogram.7, 14, 22 The three melting points can
therefore be assigned as Tm(CH2) = 344.4 K, Tm(CH3) = 357.0 K, and Tm(Fab) = 362.7
K.14, 43
One possibility for estimating ΔHglob values associated with the three unfolding transitions
would be to use Gaussian areas. However, this is problematic if transitions are
asymmetrical and/or show significant overlap (as for T > 350 K in Figure 4.4B).7, 21 In our
case, Gaussian 3 has a smaller area than Gaussian 2, which is inconsistent with the fact that
ΔHglob(Fab) is known to be larger than ΔHglob(CH3).7, 14, 22 To sidestep this issue, ΔHglob
values were determined from the area under the baseline-corrected thermogram, using the
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blue vertical lines in Figure 4.4B as integration bounds. The integration results were
divided by two because NISTmAb contains two CH2, two CH3, and two Fab (Figure 4.1)
and because each of these moieties acts as an independent unfolding unit.76 The resulting
enthalpies are ΔHglob(CH2) = 385 kJ mol-1, ΔHglob(CH3) = 694 kJ mol-1, and ΔHglob(Fab)
= 1153 kJ mol-1. The ΔHglob and Tm values govern the global unfolding free energy of the
three moieties according to27

ΔGglob(T) = ΔHglob × (1 – T/Tm)
Equation 4.9
which yields the plots of Figure 4.4C-E. In earlier work on myoglobin on Chapter 2, we
used a more complex ΔGglob expression that considered ΔCp of the unfolding transition,
causing ΔGglob(T) to be curved. The complexity of IgG1 unfolding dictates that DSC data
are generally analyzed using the approximation that ΔCp = 0 approximation, corresponding
to the linear expression of equation 4.9.7, 16 Luckily, the ΔCp-related curvature of ΔGglob(T)
only affects the HDX behavior of proteins that are significantly destabilized at low T, with
possible cold unfolding.77 For IgG1 proteins such effects can become relevant below -20
°C,78 i.e., not in the T range considered here. Hence, the linear ΔGglob(T) profiles of Figure
4.4C-E are adequate for the purpose of this work.
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Figure 4.4. DSC analysis of NSTmAb. (A) Uncorrected thermogram, displaying the heat
capacity Cp vs. temperature. The range selected to serve as aggregation background is
highlighted by dots. Also shown is the corresponding polynomial background
interpolation. (B) Background-corrected thermogram with Gaussian components and
overall fit. Blue vertical lines indicate integration bounds for ΔH calculations. (C-E)

Gglob(T) profiles extracted from panel B for the CH2, CH3, and Fab moieties.
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4.3.2

T-Dependent HDX Analyses for Selected Peptides.

We previously applied the thermodynamic framework of equations 4.1-4.7 to myoglobin
inChapter 2. To assess if this framework is also suitable for modeling the T-dependent
HDX behavior of the IgG1 studied here, we initially focused on individual NISTmAb
peptides that exhibited different types of %D(t, T) profiles (Figures 4.5, 4.6). To reduce the
number of fitting parameters, we assumed that residues in close sequence proximity share
the same ΔHloc/ΔSloc/ΔGopU parameters, as suggested by the foldon model.29,

79

Accordingly, the sequence was dissected into segments of three consecutive residues, each
of which was given its own ΔHloc/ΔSloc/ΔGopU parameters. In a few cases this procedure
did not yield satisfactory fits, necessitating the use of two-residue segments and, on rare
occasions, one-residue segments. The ΔHloc/ΔSloc/ΔGopU parameters obtained in this way
capture the combined effects of local and global dynamics. Of note, HDX is always
mediated by the fluctuation with the lowest ΔG (the largest Kop).29 Thus, depending on T,
either ΔGloc(T) or ΔG*glob(T) may be the prevalent factor for any given NH segment.
Figure 4.5A shows %D(t, T) for heavy chain Fab peptide 5-19. Based on the nearexponential rise of kch(T) in Figure 4.3B, one might have expected that %D(t,T) profiles
should exhibit a sudden and very steep increase as T is raised. Surprisingly, the %D data
of Figure 4.5A show a very different behavior, i.e., a near-linear increase. Our framework
was able to capture this near-linear behavior, evident from the close agreement between
fitted and experimental data (Figure 4.5A). Panels B-E illustrate how the overall HDX
behavior of peptide 5-19 can be dissected into staggered contributions from individual NH
sites, some of which get deuterated at low T (Figure 4.5D) while others undergo HDX at
much higher temperatures (Figure 4.5C). All these deuteration events were attributed to
local fluctuations, as evidenced by the ΔGloc profiles in Figure3F-I.
The DSC data of Figure 4.4 revealed that Tm(Fab) = 362.7 K, implying that global
opening/closing fluctuations become prevalent around this temperature.18, 19 Figure 4.5
illustrates two different scenarios related to the role of these global fluctuations. (1) Amides
7-10 and 15-17 are completely deuterated at Tm(Fab), such that global opening/closing has
no effect on their HDX behavior (Figure 4.5B/D). Any ΔGopU value is compatible with the
experimental data under such conditions. The absence of ΔG*glob profiles in Figure 4.5F/H
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reflects the indeterminate nature of ΔGopU in this scenario. (2) Amides 11-13 and 18-19
undergo deuteration around Tm(Fab), i.e., range that should be affected by global
fluctuations (Figure 4.5C/E). Surprisingly, inclusion of these global fluctuations with
ΔGopU = 0 resulted in fits that were irreconcilable with experiments (Figure 4.5J-R). The
situation could be remedied by invoking a ΔGopU >> 0 value to ensure that ΔG*glob
remained above ΔGloc at all temperatures. ΔGopU = 100 kJ mol-1 in Figure 4.5G/I resulted
in excellent agreement with the experimental data (Figure 4.5A), but this ΔGopU only
represents a lower limit because any value greater than 100 kJ mol-1 would yield an equally
good fit. Later, when discussing global fitting results, we will make the case that these very
high ΔGopU values are related to protein aggregation.
%D profiles of light chain Fab peptide 46-53 displayed a sigmoidal temperature
dependence (Figure 4.6A). Profiles with this shape were readily modeled on the basis of
local fluctuations (Figure 4.6B-E). Similar to Figure 4.5, global dynamics were not
involved in deuteration of peptide 46-53. ΔGopU was indeterminate for amides 48-50, while
ΔGopU = 100 kJ mol-1 was assigned to 51-53.
CH2 peptide 269-280 exemplifies a case where global fluctuations did make their presence
felt as a steep increase close to Tm(CH2) in the experimental data (Figure 4.6F). This steep
increase is caused by the ΔG*glob profiles that dip below ΔGloc close to the melting
temperature (Figures 4.6M/N), such that global fluctuations trigger deuteration of amides
276-280. When combined with the local dynamics of sites 271-275 (Figure 4.6K/L),
excellent agreement with the experimental data was obtained (Figure 4.6F).
In summary, Figures 4.5 and 4.6 demonstrate that the thermodynamic framework of
equations 4.1-4.7 can successfully capture experimental %D profiles that represent vastly
different T-dependent shapes. Most of the deuteration events were attributed to local
fluctuations. In addition, one of the peptides illustrated a case of HDX being driven by
global dynamics; this scenario is encountered whenever ΔG*glob dips below ΔGloc (Figure
4.6M/N). Global dynamics were not involved in the other deuteration processes of Figures
4.5/4. Such a lack of global involvement can arise if amides are already deuterated around
Tm (Figures 4.5B/D, 4.6G/H). ΔGopU is indeterminate in such cases, and no numerical
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values will be reported. Global dynamics are also irrelevant if they have a large ΔGopU,
causing ΔG*glob to hover above ΔGloc at all temperatures (Figures 4.5G/I, 4E). ΔGopU for
the latter scenario will be reported as 100 kJ mol-1, although this value only represents a
lower limit.

Figure 4.5. Temperature-dependent HDX kinetics of heavy chain Fab peptide 5-19,
analyzed using the thermodynamic model of equation 4.1-4.7. (A) Experimental data (dots)
and fits (lines). (B-E) Fitted HDX profiles of backbone sites. Each panel shows data for
one NH, identified by a large number. Smaller numbers identify the remaining NH sites in
the segment. (F-I) Free energy profiles associated with panels B-E (ΔGloc is shown as solid
lines, ΔG*glob as dashed lines). (J-R) These bottom panels mirror the top panels, except
that ΔGopU was changed from 100 kJ mol-1 to zero in P/R, yielding global dynamics that
are irreconcilable with experiments (illustrated in panel J).
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Figure 4.6. Thermodynamic analysis of temperature-dependent HDX kinetics for (A-E)
light chain peptide 46-53 in the Fab region, and (F-N) heavy chain peptide 269-280 in the
CH2 region. For additional details, see text and caption of Figure 4.5A-I.

4.3.2.1

Global Fitting of T-Dependent HDX Data

Encouraged by the successful application of our thermodynamic framework to individual
peptides (Figures 4.5, 4.6), we aimed to determine ΔHloc/ΔSloc/ΔGopU values for the entire
NISTmAb. Extracting these parameters for each of the 613 non-proline residues would be
an insurmountable task. Several safeguards were implemented to narrow down the range
of possible solutions. (1) As for the single-peptide analyses discussed previously, we
assumed that segments of three (sometimes fewer, see Table 4.1) consecutive residues
share the same ΔHloc/ΔSloc/ΔGopU values. (2) Global fitting is a method that greatly
improves the robustness of results73, 74, 80-82 [note that “global fitting” is unrelated to “global
unfolding”]. Here we implemented a global fitting strategy that required ΔHloc/ΔSloc/ΔGopU
parameters to be identical for all segments that were shared across overlapping peptides,

116

using the least-square optimization strategy of equation 4.8. A total of 80 peptides were
included, for a sequence coverage 73%. Figure 4.9 shows these overlapping peptides, as
well as segment boundaries. ΔHloc was capped at 100 kJ mol-1, in line with energetic
estimates of local unfolding events.83 (3) Instead of focusing on T-dependent HDX data at
a single time point, we simultaneously fitted four complete temperature profiles for t = 15
s, 30 s, 2 min, and 20 min for all peptides.
Gratifyingly, our global fitting strategy succeeded in finding a set of ΔHloc/ΔSloc/ΔGopU
values that provided excellent agreement between calculated and experimental %D(t,T)
profiles for all peptides, all temperatures, and all time points (Figure 4.11). The fitted
thermodynamic parameters obtained in this way are summarized in Figure 4.10.
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Table 4.1 (continued following page). Assignment of segments to protein regions and
residue range for global fitting results, see Figure 4.3.

LIGHT CHAIN
Segment Region Residues
1
VL
7-9
2
VL 10-11
3
VL
12,13
4
VL 37-40
5
VL 41-43
6
VL 44-45
7
VL 48-50
8
VL 51-53
9
VL 56-58
10
VL 59-61
11
VL 62-64
12
VL 65-67
13
VL 68-70
14
VL 71-73
15
VL 74-75
16
VL 76-77
17
VL 78-80
18
VL 81-82
19
CL
120
20
CL
121
21
CL
122
22
CL 123-125
23
CL 126-128
24
CL 129-131
25
CL
132
26
CL
137
27
CL
138
28
CL
139
29
CL 140-142
30
CL 143-145
31
CL 146-148
32
CL 149-151
33
CL 152-154
34
CL 155-157
35
CL 158-160
HEAVY CHAIN

LIGHT CHAIN (cont'd)
Segment Region Residues
36
CL 163-165
37
CL 166-168
38
CL 169-171
39
CL 172-173
40
CL 174-175
41
CL 176-177
42
CL
178
43
CL 180-182
44
CL 183-185
45
CL 186-188
46
CL 189-191
47
CL 192-194
48
CL 195-197
49
CL 198-199
50
CL 200-201
51
CL 202-204
52
CL 205-207
53
CL 208-210
54
CL 211-213

HEAVY CHAIN (cont'd)

HEAVY CHAIN (cont'd)
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Segment Region Residues
1
VH
7-10
2
VH 11_14
3
VH 15-17
4
VH 18-19
5
VH
23
6
VH 24-25
7
VH 26-27
8
VH
30
9
VH
31
10
VH
32
11
VH 33-35
12
VH 36-38
13
VH 39-41
14
VH 42-45
15
VH 46-47
16
VH
48
17
VH 53-55
18
VH 56-58
19
VH 59-61
20
VH 62-64
21
VH 65-67
22
VH 68-70
23
VH 71-73
24
VH 74-76
25
VH 77-79
26
VH 80-82
27
VH 85-87
28
VH 88-90
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Figure 4.7 (A). NISTmAb light chain peptides detected after peptic digestion.
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Figure 4.7. (B) NISTmAb heavy chain peptides detected after
peptic digestion.
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Figure 4.8. (A) NISTmAb light chain peptides used for global analysis.
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Figure 4.8 (B).) NISTmAb heavy chain peptides used for global analysis.
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Figure 4.9.(A) Light chain peptide map for global fitting. Clusters of overlapping peptides
were grouped together as indicated by the different colors. Vertical black lines indicate
segment boundaries. All NH sites within a segment and across all overlapping peptides
were fitted with the same Hloc/Sloc/GopU parameters. The first two residues of each
peptide (gray) were not considered due to back exchange. Pro residues are also shown in
gray, reflecting their lack of NH sites [continued following page].
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Figure 4.9 (B) Heavy chain peptide map for global fitting.

4.3.2.2

Local Dynamics: ΔHloc and ΔSloc.

Almost all local fluctuations of NISTmAb were characterized by ΔHloc > 0 and ΔSloc > 0
(Figure 4.10A-D), causing ΔGloc to decrease with increasing temperature (equation 4.4). In
other words, the free energy penalty associated with local unfolding became less severe at
high T. The endothermic (ΔHloc > 0) nature of these local fluctuations reflects the fact that
energy input is required to disrupt intramolecular contacts that are associated with local
NHclosed → NHopen events. These contacts include NH···OC hydrogen bonds,83 but also
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hydrophobic and van der Waals interactions, as well as salt bridges.84 The entropy increase
(ΔSloc > 0) of the NHclosed → NHopen transitions reflects the increased conformational
freedom of the locally unfolded segments.84
The prevalence of ΔHloc > 0 and ΔSloc > 0 for local fluctuations of NISTmAb is somewhat
different from myoglobin, where a multitude of segments showed “noncanonical” behavior
with ΔHloc < 0 and ΔSloc < 0 (showed already in chapter 2). Local unfolding is enthalpically
driven in such noncanonical cases, likely by the tight hydration of the unfolded segments.85,
86

In NISTmAb only very few segments displayed noncanonical behavior, seen from the

sparsity of negative data points in Figure 4.10A-D.
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Figure 4.10. Thermodynamic parameters obtained by global fitting of all experimental %D
profiles at all temperatures and all time points (see Figure 4.11 for fitted curves). (A, B)
ΔHloc, (C, D) ΔSloc, (E, F) ΔGglobU. Missing data in panels E/F correspond to indeterminate
ΔGglobU values. See Table 4.1 for the assignment of segment numbers to residue numbers.
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Figure 4.11. (A) Experimental %D(t, T) data (points) and global fits (lines) for light chain
Fab peptides. Error bars are smaller than the data points in most cases.
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Figure 4.11 (B) Experimental %D(t, T) data (points) and global fits (lines) for heavy chain
Fab peptides. Error bars are smaller than the data points in most cases.
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4.3.2.3

Global Dynamics of CH2 and CH3 Moieties

Global N ↔ U fluctuations between the native and the unfolded state become prevalent in
the vicinity of Tm.19 For small single-domain proteins these global fluctuations
simultaneously affect all residues. However, for large proteins with distinct domains (such
as IgG1s) the situation is different. In this work, “global” does not refer to the entire
NISTmAb, but it separately applies to the CH2, CH3, and Fab moieties. Approximating
these moieties as individual global units is justified because each of them undergoes
unfolding with a characteristic Tm, quite independently of the other protein regions.7, 14, 22,
75

We will first discuss global dynamics of CH2 and CH3. It might be expected that N ↔ U
fluctuations close to the corresponding Tm values are equivalent to the NHclosed ↔ NHopen
dynamics that mediate HDX (equation 4.1). In such a case, backbone amides in the
thermally unfolded moieties would be completely unprotected, akin to NH sites in
dipeptide model compounds.46 However, it is known that many thermally unfolded
proteins possess residual protection, suggesting that globally-mediated HDX requires two
steps (N ↔ Uclosed ↔ Uopen), where the second step produces NHopen sites that are required
for deuteration. Within our thermodynamic framework, such two-step transitions are
captured via equation 4.5, where Gglob(T) refers to the N ↔ Uclosed transitions that can be
probed by DSC, while GopU refers to Uclosed ↔ Uopen (showed in Chapter 2). Figure 4.10F
shows that many CH2 and CH3 segments had GopU values around 20 – 50 kJ mol-1,
revealing that HDX of the corresponding segments indeed proceeds via N ↔ Uclosed ↔
Uopen. In free energy plots such as Figure 4.6M/N, these GopU contributions shift G*glob
upward, rendering the formation of NHopen sites less favorable than the initial N ↔ Uclosed
events. To summarize, CH2 and CH3 global fluctuations do not directly involve fully
unprotected random coil structures. Instead, the significant GopU contributions in Figure
4.10F highlight the presence of non-native intrachain contacts in the unfolded state. These
non-native contacts have to transiently open up for HDX to proceed.
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4.3.2.4

Fab Global Dynamics and Protein Aggregation

For the single Fab peptide examined in Figure 4.5, the inclusion of global fluctuations
produced irreconcilable discrepancies with the experimental data (Figure 4.5J). Agreement
between fits and experiments could only be achieved by invoking a very large GopU value,
which we arbitrarily assigned as 100 kJ mol-1. The fitting results of Figure 4.10E/F reveal
that this GopU = 100 kJ mol-1 scenario applied to the entire Fab moiety for both heavy and
light chains, implying that global dynamics were not involved in Fab deuteration. This Fab
behavior is in striking contrast to CH2 and CH3, where global fluctuations were required
for fitting the experimental data.
How is it possible that global fluctuations of Fab do not contribute to deuteration? We
attribute this peculiar effect to irreversible NISTmAb aggregation, which takes place close
to Tm(Fab) as reported in previous studies,7, 17, 20, 21, 43 and as seen in the DSC data of Figure
4.4B. This aggregation was also apparent by visual inspection of heated samples (Figure
4.12). The Linderstrom-Lang HDX model relies on NHclosed ↔ NHopen fluctuations that are
fully reversible (equation 4.1).29 The aforementioned N ↔ Uclosed ↔ Uopen dynamics of the
CH2 and CH3 moieties fall under this umbrella. However, the Fab behavior is different.
The fact that irreversible aggregation starts to take place around Tm(Fab) implies that global
Fab dynamics cannot be described as N ↔ Uclosed ↔ Uopen, but that they produce aggregates
via either N ↔ Uclosed → Aggregated, or N ↔ Uclosed ↔ Uopen → Aggregated. Conventional
HDX-MS analyses strategies (equation 4.1) are not applicable under such irreversible
scenarios. Our HDX-MS data are consistent with the view that aggregated NISTmAb is
resistant to peptic digestion, akin to other types of aggregates.87 Any protease-resistant
species is unobservable in HDX-MS, and it will therefore not contribute to the
experimentally observed %D values. Instead, the experimental data only report on the subpopulation of proteins that remain soluble. For this reason, the very large GopU of 100 kJ
mol-1 throughout the Fab moiety (Figure 410) should not be interpreted in the context of
Uclosed ↔ Uopen transitions (Chapter 2). Under the conditions encountered here, these very
large GopU values represent the hallmark of irreversible aggregation.
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Finally, we note that gaps in the bar diagrams of Figure 4.10E/F should not be interpreted
as GopU = 0. Instead, they represent segments where GopU was indeterminable, i.e., where
any value GopU > 0 is compatible with the experimental data. The origin of this effect has
been discussed above (Figures 4.5 and 4.6). This nature of these indeterminate values is
very different from the GopU = 100 kJ mol-1 data points. In the former case, any value is
consistent with the experiments; in the latter case, only a very large value provides a good
fit with the measured %D values.

Figure 4.12. Photograph of 6.6 µM NISTmAb in an Eppendorf vial after 10 min at 95 °C,
pH 6.32. The presence of aggregated protein (white amorphous precipitate) is readily
apparent.

4.4

Conclusions

Traditional HDX-MS analyses involve fitting of time-dependent data to a sum of
exponentials, providing amplitudes and apparent rate constants for individual peptides.72
Although such analyses can uncover interesting trends, the fits are largely descriptive
instead of directly uncovering intrinsic protein features. The analysis strategy pursued in
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this work goes one step further, i.e., it uncovers thermodynamic parameters that govern the
structural dynamics of different protein regions for different time points, and across
temperatures ranging from near freezing to almost boiling. We originally devised the
framework used here for the small single-domain protein myoglobin (Chapter 2). It was
not obvious if the same strategy would be applicable to NISTmAb, a complicated multidomain system where dynamics, unfolding, and aggregation are closely intertwined.
Fortunately, global analysis of %D(t,T) produced excellent fits for all NISTmAb peptides,
verifying the suitability of our strategy for complex protein therapeutics.
The application of our thermodynamic model to NISTmAb requires a disclaimer regarding
the role of GopU. Originally, this parameter was designed to capture residual protection of
a globally unfolded protein (Chapter 2), as seen in the current work for CH2 and CH3.
However, the entire Fab region had to be fitted with an extremely large GopU value of 100
kJ mol-1 not because of residual protection, but to account for aggregation.
Our data reveal that increasing temperature causes enhanced deuteration. The biophysical
foundation of this effect is surprisingly complicated, as it reflects the combination of at
least four factors. (1) To a large extent, the T-dependence of %D arises from the nearexponential increase of kch(T), illustrated in Figure 4.3B. (2) Kloc and K*glob in equation 4.5
govern the population of NHopen sites which are required for HDX. These equilibrium
constants can be expressed via their respective ΔG values (equation 4.3). Even if these ΔG
values were constant, increasing temperature would boost HDX because the population of
Boltzmann-excited NHopen sites is proportional to exp(ΔG/RT). (3) At relatively low T,
where protein dynamics are governed by local fluctuations, the population of NHopen sites
is further enhanced by the fact that ΔGloc becomes less positive with increasing T for most
segments, i.e., those with ΔHloc > 0 and ΔSloc > 0 (Figure 4.10A-D). (4) ΔG*glob becomes
less positive with increasing T, with a slope that is steeper than that of ΔGloc. This steep
slope causes ΔG*glob to drop below ΔGloc in the vicinity of Tm, such that global fluctuations
become the dominant contributor to deuteration (exemplified in Figure 4.6M/N). The
analysis strategy pursued in this work allows to clearly distinguish between the four factors.
Factors #1 and #2 are rather trivial, whereas factors #3 and #4 provide a direct window into
the inner workings of the protein.
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Overall, we hope that this work will encourage practitioners to consider time and
temperature as equivalent variables in HDX-MS experiments, specifically for
investigations of mAbs and other protein therapeutics. Complete deuteration of highly
protected NH sites can take days at ambient temperature,45 whereas complete deuteration
can be achieved within ~20 minutes upon heating the samples. With suitable automation,
it should be possible to streamline the temperature-dependent HDX workflow employed
here, such that the dynamic features across the entire protein become experimentally
accessible in very short time windows. The thermodynamic model used here represents a
quantitative analysis tool for deciphering the various factors that govern the temperatureand time-dependence of protein deuteration. Spatially-resolved data obtained by Tdependent HDX-MS provide a more detailed picture than DSC or related techniques that
only report on global unfolding.

136

4.5

1

References

Leader, B., Q. J. Baca, D. E. Golan, Nature Reviews Drug Discovery 2008, 7, 21.

2
Lagassé, H. A. D., A. Alexaki, V. L. Simhadri, N. H. Katagiri, W. Jankowski,
F1000 Faculty Rev. 2017, 113, 1.
3
Kaltashov, I. A., C. E. Bobst, J. Pawlowski, G. B. Wang, J. Pharm. Biomed. Anal.
2020, 184,
4

Castelli, M. S., P. McGonigle, P. J. Hornby, Pharmacol. Res. Perspect. 2019, 7, 11.

5

Lambert, J. M., A. Berkenblit, Annual review of medicine 2018, 69, 191.

6

Vidarsson, G., G. Dekkers, T. Rispens, Frontiers in Immunology 2014, 5,

7

Ionescu, R. M., J. Vlasak, C. Price, M. Kirchmeier, J. Pharm. Sci. 2008, 97, 1414.

8
Chen, W., L. Kong, S. Connelly, J. M. Dendle, Y. Liu, I. A. Wilson, E. T. Powers,
J. W. Kelly, ACS Chem. Biol. 2016, 11, 1852.
9

Liu, H. C., K. May, Mabs 2012, 4, 17.

10

Bye, J. W., L. Platts, R. J. Falconer, Biotechnol. Lett. 2014, 36, 869.

11
Goldberg, D. S., R. A. Lewus, R. Esfandiary, D. C. Farkas, N. Mody, K. J. Day, P.
Mallik, M. B. Tracka, S. K. Sealey, H. S. Samra, J. Pharm. Sci. 2017, 106, 1971.
12
Toth, R. T., S. E. Pace, B. J. Mills, S. B. Joshi, R. Esfandiary, C. R. Middaugh, D.
D. Weis, D. B. Volkin, J. Pharm. Sci. 2018, 107, 1009.
13

Capelle, M. A. H., R. Gurny, T. Arvinte, Eur. J. Pharm. Biopharm. 2007, 65, 131.

14

Menzen, T., W. Friess, J. Pharm. Sci. 2013, 102, 415.

15

Arthur, K. K., N. Dinh, J. P. Gabrielson, J. Pharm. Sci. 2015, 104, 1548.

16

Garidel, P., A. Eiperle, M. Blech, J. Seelig, Biophys. J. 2020, 118, 1067.

17

Wang, G. B., P. V. Bondarenko, I. A. Kaltashov, Analyst 2018, 143, 670.

18

Zhou, Y., C. K. Hall, M. Karplus, Protein Sci. 1999, 8, 1064.

19

Privalov, P. L., N. N. Khechinashvili, J. Mol. Biol. 1974, 86, 665.

20

Vermeer, A. W. P., W. Norde, Biophys. J. 2000, 78, 394.

137

21

Akazawa-Ogawa, Y., H. Nagai, Y. Hagihara, Biophys. Rev. 2018, 10, 255.

22

Garber, E., S. J. Demarest, Biochem. Biophys. Res. Commun. 2007, 355, 751.

23

Lang, B. E., K. D. Cole, Biotechnol. Prog. 2017, 33, 677.

24

Fukuda, J., T. Iwura, S. Yanagihara, K. Kano, Anal. Sci. 2015, 31, 1233.

25
Edgeworth, M. J., J. J. Phillips, D. C. Lowe, A. D. Kippen, D. R. Higazi, J. H.
Scrivens, Angew. Chem. Int. Ed. 2015, 54, 15156.
26

Niesen, F. H., H. Berglund, M. Vedadi, Nat. Protocols 2007, 2, 2212.

27

Swint, L., A. D. Robertson, Protein Sci. 1993, 2, 2037.

28
Frauenfelder, H., G. Chen, J. Berendzen, P. W. Fenimore, H. Jansson, B. H.
McMahon, I. R. Stroe, J. Swenson, R. D. Young, Proc. Natl. Acad. Sci. U.S.A. 2009, 106,
5129.
29

Bai, Y., T. R. Sosnick, L. Mayne, S. W. Englander, Science 1995, 269, 192.

30
Hanoian, P., C. T. Liu, S. Hammes-Schiffer, S. Benkovic, Accounts Chem. Res.
2015, 48, 482.
31
Murcia Rios, A., S. Vahidi, S. D. Dunn, L. Konermann, J. Am. Chem. Soc. 2018,
140, 14860.
32

Xiao, Y., G. S. Shaw, L. Konermann, J. Am. Chem. Soc. 2017, 139, 11460.

33

Balchin, D., M. Hayer-Hartl, F. U. Hartl, Science 2016, 353, 42.

34
Rob, T., P. Liuni, P. K. Gill, S. L. Zhu, N. Balachandran, P. J. Berti, D. J. Wilson,
Anal. Chem. 2012, 84, 3771.
35
Masson, G. R., J. E. Burke, N. G. Ahn, G. S. Anand, C. H. Borchers, S. Brier, G.
M. Bou-Assaf, J. R. Engen, S. W. Englander, J. H. Faber, R. A. Garlish, P. R. Griffin, M.
L. Gross, M. Guttman, Y. Hamuro, A. J. R. Heck, D. Houde, R. E. Iacob, T. J. D. Jorgensen,
I. A. Kaltashov, J. P. Klinman, L. Konermann, P. Man, L. Mayne, B. D. Pascal, D.
Reichmann, M. Skehel, J. Snijder, T. S. Strutzenberg, E. S. Underbakke, C. Wagner, T. E.
Wales, B. T. Walters, D. D. Weis, D. J. Wilson, P. L. Wintrode, Z. Zhang, J. Zheng, D. C.
Schriemer, K. D. Rand, Nat. Methods 2019, 16, 595.
36
James, E. I., T. A. Murphree, C. Vorauer, J. R. Engen, M. Guttman, Chem. Rev.
2022, 122, 7562.
37

Hageman, T. S., M. S. Wrigley, D. D. Weis, Anal. Chem. 2021, 93, 6980.

38
Pirrone, G. F., H. Wang, N. Canfield, A. S. Chin, T. A. Rhodes, A. A. Makarov,
Analytical Chemistry 2017, 89, 8351.

138

39
Hudgens, J. W., E. S. Gallagher, I. Karageorgos, K. W. Anderson, J. J. Filliben, R.
Y. C. Huang, G. D. Chen, G. M. Bou-Assaf, A. Espada, M. J. Chalmers, E. Harguindey,
H. M. Zhang, B. T. Walters, J. Zhang, J. Venable, C. Steckler, I. Park, A. Brock, X. J. Lu,
R. Pandey, A. Chandramohan, G. S. Anand, S. N. Nirudodhi, J. B. Sperry, J. C. Rouse, J.
A. Carroll, K. D. Rand, U. Leurs, D. D. Weis, M. A. Al-Naqshabandi, T. S. Hageman, D.
Deredge, P. L. Wintrode, M. Papanastasiou, J. D. Lambris, S. Li, S. Urata, Anal. Chem.
2019, 91, 7336.
40
Trabjerg, E., R. U. Jakobsen, S. Mysling, S. Christensen, T. J. D. Jorgensen, K. D.
Rand, Anal. Chem. 2015, 87, 8880.
41
Zhu, S. L., P. Liuni, L. Ettorre, T. Chen, J. Szeto, B. Carpick, D. A. James, D. J.
Wilson, Biochemistry 2019, 58, 646.
42
Bonnington, L., I. Lindner, U. Gilles, T. Kailich, D. Reusch, P. Bulau, Anal. Chem.
2017, 89, 8233.
43
Hamuro, Y., M. G. Derebe, S. Venkataramani, J. F. Nemeth, Protein Sci. 2021, 30,
1686.
44
Houde, D., J. Arndt, W. Domeier, S. Berkowitz, J. R. Engen, Anal. Chem. 2009,
81, 2644.
45
Skinner, J. J., W. K. Lim, S. Bedard, B. E. Black, S. W. Englander, Protein Sci.
2012, 21, 996.
46
Bai, Y., J. S. Milne, L. Mayne, S. W. Englander, Proteins: Struct., Funct., Genet.
1993, 17, 75.
47
Calugareanu, D., I. R. Moller, S. G. Schmidt, C. J. Loland, K. D. Rand, J. Mol.
Biol. 2022, 434, 15.
48
Coales, S. J., S. Y. E, J. E. Lee, A. Ma, J. A. Morrow, Y. Hamuro, Rapid Commun.
Mass Spectrom. 2010, 24, 3585.
49

Gao, S., J. P. Klinman, Curr. Op. Struct. Biol. 2022, 75, 102434.

50
Liang, Z.-X., T. Lee, K. A. Resing, N. G. Ahn, J. P. Klinman, Proc. Natl. Acad.
Sci. U.S.A. 2004, 101, 9556.
51
Goswami, D., S. Devarakonda, M. J. Chalmers, B. D. Pascal, B. M. Spiegelman, P.
R. Griffin, J. Am. Soc. Mass Spectrom. 2013, 24, 1584.
52

Klinman, J. P., Accounts Chem. Res. 2015, 48, 449.

53
Xiao, H., J. K. Hoerner, S. J. Eyles, A. Dobo, E. Voigtman, A. I. Mel'Cuk, I. A.
Kaltashov, Protein Sci. 2005, 14, 543.

139

54
Xiao, P., D. Bolton, R. A. Munro, L. S. Brown, V. Ladizhansky, Nat. Commun.
2019, 10,
55

Best, R. B., M. Vendruscolo, Structure 2006, 14, 97.

56
Nguyen, D., L. Mayne, M. C. Phillips, S. W. Englander, J. Am. Soc. Mass Spectrom.
2018, 29, 1936.
57

Covington, A. K., R. A. Robinson, R. G. Bates, J. Phys. Chem. 1966, 70, 3820.

58

Ratcliff, K., S. Marqusee, Biochemistry 2010, 49, 5167.

59

Bowler, B. E., Curr. Op. Struct. Biol. 2012, 22, 4.

60

Keppel, T. R., B. A. Howard, D. D. Weis, Biochemistry 2011, 50, 8722.

61
Zhu, S. L., A. Shala, A. Bezginov, A. Sljoka, G. Audette, D. J. Wilson, PloS One
2015, 10, 1.
62
Ng, Y. K., N. N. Tajoddin, P. M. Scrosati, L. Konermann, J. Phys. Chem. B 2021,
125, 13099.
63
Gallagher, D. T., I. Karageorgos, J. W. Hudgens, C. V. Galvin, Data Brief 2018,
16, 29.
64

Bergonzo, C., D. T. Gallagher, J. Res. Natl. Inst. Stand. Technol. 2021, 126, 6.

65
Pabon, J. P. R., B. A. Kochert, Y. H. Liu, D. D. Richardson, D. D. Weis, J. Pharm.
Sci. 2021, 110, 2355.
66
Groves, K., A. Cryar, S. Cowen, A. E. Ashcroft, M. Quaglia, J. Am. Soc. Mass
Spectrom. 2020, 31, 553.
67

Glasoe, P. K., F. A. Long, J. Phys. Chem. 1960, 64, 188.

68
Xiao, Y., M. Li, R. Larocque, F. Zhang, A. Malhotra, J. Chen, R. J. Linhardt, L.
Konermann, D. Xu, J. Biol. Chem. 2018, 293, 17523.
69
Zhang, H. M., S. M. McLoughlin, S. D. Frausto, H. L. Tang, M. R. Emmett, A. G.
Marshall, Anal. Chem. 2010, 82, 1450.
70
Distler, U., J. Kuharev, P. Navarro, Y. Levin, H. Schild, S. Tenzer, Nat. Methods
2014, 11, 167.
71

Peterle, D., T. E. Wales, J. R. Engen, Anal. Chem. 2022, 94, 10142.

72

Smith, D. L., Y. Deng, Z. Zhang, J. Mass Spectrom. 1997, 32, 135.

140

73
Skinner, S. P., G. Radou, R. Tuma, J. J. Houwing-Duistermaat, E. Paci, Biophys. J.
2019, 116, 1194.
74
Fajer, P. G., G. M. Bou-Assaf, A. G. Marshall, J. Am. Soc. Mass Spectrom. 2012,
23, 1202.
75

Ito, T., K. Tsumoto, Protein Sci, 2013, 22, 1542.

76

Feige, M. J., S. Walter, J. Buchner, J. Mol. Biol. 2004, 344, 107.

77
Privalov, P. L., Y. V. Griko, S. Y. Venyaminov, V. P. Kutyshenko, J. Mol. Biol.
1986, 190, 487.
78

Lazar, K. L., T. W. Patapoff, V. K. Sharma, mAbs 2010, 2, 42.

79
Weinkam, P., J. Zimmermann, F. E. Romesberg, P. G. Wolynes, Acc. Chem. Res.
2010, 43, 652.
80

Hamuro, Y., J. Am. Soc. Mass Spectrom. 2017, 28, 486.

81
Kan, Z. Y., B. T. Walters, L. Mayne, S. W. Englander, Proc. Natl. Acad. Sci. U.S.A.
2013, 110, 16438.
82
Gessner, C., W. Steinchen, S. Bedard, J. J. Skinner, V. L. Woods, T. J. Walsh, G.
Bange, D. P. Pantazatos, Sci. Rep. 2017, 7,
83
Pace, C. N., H. L. Fu, K. L. Fryar, J. Landua, S. R. Trevino, D. Schell, R. L.
Thurlkill, S. Imura, J. M. Scholtz, K. Gajiwala, J. Sevcik, L. Urbanikova, J. K. Myers, K.
Takano, E. J. Hebert, B. A. Shirley, G. R. Grimsley, Protein Sci. 2014, 23, 652.
84

Kazlauskas, R., Chem. Soc. Rev. 2018, 47, 9026.

85

Yang, C., S. Jang, Y. Pak, Nat. Commun. 2014, 5,

86
Dias, C. L., T. Ala-Nissila, M. Karttunen, I. Vattulainen, M. Grant, Phys. Rev. Lett.
2008, 100, 118101.
87
Sole-Domenech, S., A. V. Rojas, G. G. Maisuradze, H. A. Scheraga, P. Lobel, F.
R. Maxfield, Proc. Natl. Acad. Sci. U. S. A. 2018, 115, 1493.

141

5

Chapter 5. Conclusions

5.1 Summary
The work in this thesis expands the analytical capabilities of HDX-MS to study thermal
stability and thermodynamics of small globular protein to large, multidomain protein.
Detailed information on chemical and physical stability is required to develop and
commercialize novel protein drugs. In this regard, it is essential to establish advanced
methods for providing comprehensive information for protein stability.
H/D exchange (HDX) mass spectrometry (MS) is a widely used technique for interrogating
protein structure and dynamics. Backbone HDX is mediated by opening/closing
(unfolding/refolding) fluctuations. In traditional HDX-MS, proteins are incubated in D2O
as a function of time at constant temperature (T). There is an urgent need to complement
this traditional approach with experiments that probe proteins in a T-dependent fashion,
e.g., for assessing the stability of therapeutic antibodies. In Chapter 2, a fundamental
workflow is built for analyzing temperature- dependent HDX-MS. A key problem with
such studies is the absence of strategies for interpreting HDX/MS data in the context of Tdependent protein dynamics. Specifically, it has not been possible thus far to separate Tinduced changes in the chemical labeling step (kch) from thermally enhanced protein
fluctuations. Focusing on myoglobin, we solved this problem by dissecting T-dependent
HDX-MS profiles into contributions from kch(T), as well as local and global protein
dynamics. Experimental profiles started off with surprisingly shallow slopes that seemed
to defy the quasi-exponential kch(T) dependence. Just below the melting temperature (Tm)
the profiles showed a sharp increase. Our analysis revealed that local dynamics dominate
at low T, while global events become prevalent closer to Tm. About half of the backbone
NH sites exhibited a canonical scenario, where local opening/closing was associated with
positive H and S. Many of the remaining sites had negative H and S, thereby
accounting for the shallowness of the experimental HDX-MS profiles at low T. In
summary, this chapter provides practitioners with the tools to analyze proteins over a wide
temperature range, paving the way toward T-dependent high-throughput screening
applications by HDX-MS.
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Proteins that encounter unfavorable solvent conditions are prone to aggregation, a
phenomenon that remains poorly understood. In Chapter 3 we focused on myoglobin (Mb)
as model protein. Upon heating, Mb produces amorphous aggregates. Thermal unfolding
experiments at low concentration (where the aggregation is negligible), along with
centrifugation assays, imply that Mb aggregation proceeds via globally unfolded
conformers. This contrasts studies on other proteins that emphasized the role of partially
folded structures as aggregate precursors. Molecular dynamics (MD) simulations were
performed to gain insights into the mechanism by which heat-unfolded Mb molecules
associate with one another. Binding was mediated by hydrophobic contacts, along with salt
bridges that involved hydrophobically embedded Lys residues. Overall, this Chapter
provides insights into protein aggregation mechanisms.
In Chapter 4, we focused to NISTmAb, a complicated multi-domain system where
dynamics, unfolding, and aggregation are closely intertwined and we uncover
thermodynamic parameters that govern the structural dynamics of different protein regions
for different time points, and across temperatures ranging from near freezing to almost
boiling. In this regard the framework from chapter 2 was applied. Global analysis of
%D(t,T) produced excellent fits for all NISTmAb peptides, verifying the suitability of our
strategy for complex protein therapeutics. Our data reveal that increasing temperature
causes enhanced deuteration. The biophysical foundation of this effect is surprisingly
complicated, as it reflects the combination of at least four factors. The analysis strategy
pursued in this work allows to clearly distinguish between the four factors. Overall, we
hope that this work will encourage practitioners to consider time and temperature as
equivalent variables in HDX-MS experiments, specifically for investigations of mAbs and
other protein therapeutics. Complete deuteration of highly protected NH sites can take days
at ambient temperature, whereas complete deuteration can be achieved within ~20 minutes
upon heating the samples. With suitable automation, it should be possible to streamline the
temperature dependent HDX workflow employed here, such that the dynamic features
across the entire protein become experimentally accessible in very short time windows.
The thermodynamic model used here represents a quantitative analysis tool for deciphering
the various factors that govern the temperature- and time-dependence of protein
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deuteration. Spatially resolved data obtained by T-dependent HDX-MS provide a more
detailed picture than DSC or related techniques that only report on global unfolding.

5.2 Future Directions

5.2.1

Develop Instrumentation and Software to Analyze Tdependent HDX-MS Data

Temperature-dependent HDX-MS can provide valuable information about protein
thermodynamics and fluctuation, and this method would be very beneficial for assessing
protein therapeutic stability in biopharmaceutical companies. However, a key obstacle to
employing this strategy is the manual experiment procedure and time-consuming data
processing. It may come as no surprise that the global fitting of Chapters 2 and 4 required
many weeks of painstaking work, involving multiple highly complex Excel files. At the
current stage of development, such strategies will likely not be adopted by researchers in
pharmaceutical companies. It is hoped that future work will streamline this analysis process
via the development of dedicated software. Similarly, temperature-dependent HDX-MS
experiments are quite laborious. Automated equipment is available for traditional timedomain measurements. It is hoped that it will be possible to adapt such robotic platforms
for temperature-dependent measurements.

5.2.2

Computational Simulations of Aggregation for Large MultiDomain Proteins

Monoclonal antibodies are multi-domain proteins that have three different melting
temperatures. Individual domains unfold sequentially, and our observation shows antibody
remains soluble up to the temperature all the three domains are unfolded. This is in contrast
to the theory that the unfolding of one domain would be sufficient for triggering
aggregation. It raises the question of how unfolded domain is soluble and does not trigger
aggregate.
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The aggregation of protein therapeutics is one of the main challenges in biopharmaceutical
companies, and the computational simulation for this big system would provide invaluable
information for their thermal stability, which can be beneficial for the drug industry.
Moreover, it would shed additional light on other questions related to protein dynamics
and thermodynamics.

145

APPENDIX І-PERMISSIONS

146

147

148

APPENDIX II- Curriculum Vitae
Name:

Nastaran Nosrat Tajoddin

Post-secondary
Education and
Degrees:

University of Birjand
Birjand, Iran
2007-2012 B.Sc., Applied chemistry
University of Tabriz
Tabriz, Iran
2012-2015 M.Sc., Nanoscience and Nanotechnology

Honours and
Awards:

Hadis Hayatdavoudi Graduate Scholarship in Chemistry
The University of Western Ontario
2021

Related Work
Experience

Teaching Assistant
The University of Western Ontario
2018-2022

Publications:
•
Y. K. Ng, N. N. Tajoddin, P. M. Scrosati, and L. Konermann, J. Phys. Chem. B,
vol. 125, no. 48, pp. 13099–13110, 2021.
•
N. N. Tajoddin and L. Konermann, Anal. Chem., vol. 92, no. 14, pp. 10058–10067,
2020.
•
T. Hossiennejad, M. Daraie, M. M. Heravi, and N. Nosrat Tajoddin. J. Inorg.
Organomet. Polym. Mater., vol. 27, pp. 861–870, 2017.
•
S. Mohammadi, B. Sarkhosh, and N. Nosrat Tajoddin. Journal of Mater. Sci. Mater.
Electron., vol. 28, pp. 9456–9463, 2017.

